Jameson Stanford Resources (JMSN) Announces Mineral Exploration Program

LAS VEGAS, NV — (Marketwired) — 06/10/13 — Jameson Stanford Resources Corp. (OTCBB: JMSN) (the “Company”), a metals and minerals exploration, development and production company, today announces its mineral exploration strategy as well as the current status of its existing mining projects.

“Since inception, we have operated as a minerals exploration company focused on acquiring and consolidating mining claims and mineral leases with potential production and future growth through exploration discoveries,” said Michael Stanford, President and CEO of Jameson Stanford Resources. “Our current growth strategy is focused on the initiation and expansion of operations through the exploration and development of our current mining claims and mineral properties into producing projects.”

Results of the Company’s current minerals exploration and expansion programs have included the following activities:

• Commenced drilling program and open prospect pit mining on the Star Mountain/Chopar Mine following SEC Industry Guide 7, and National Instrument 43-101 protocols. 17 exploration drill holes 500′ (five hundred feet) at depth for a total of 8,500′ (eight thousand five hundred feet) of drilling completed thus far. Third party engineering and analytical reports are pending. Fifty more exploratory drilling holes have been selected from the Company’s current geologic observations, geophysical data and geochemical data.
• Acquisition of two Metalliferous Mineral Contracts from the State of Utah Trustlands Administration in areas known to carry economic concentrations of base and precious metals such as copper, lead, zinc, beryllium, bismuth, silver and gold. This acquisition expanded the Company’s land holdings by 3,324 acres (1,407 acres Star Mountain/Chopar Mine and 1,917 acres Spor Mountain Dugway Minerals, respectively).
• Mined 1,200 short tons of hard rock from two prospect pits at Spor Mountain Dugway Minerals for pilot scale run and testing. Third party engineering and analytical reports are pending.
• Stockpiled approximately 40,105 cubic yards (66,574 tons) of mineral sands at the Company’s Ogden Bay Minerals project site for near-term processing.

“The preliminary geological reports have confirmed that our sites contain substantial reserves of high-grade copper, gold and silver as well as other highly marketable metals,” added Mr. Stanford. “We have enlisted some of the top names in the mining industry to complete testing and create the necessary assay and industry reports that we believe will translate into substantial shareholder value as we get further into our next phase of production and delivery.”

Immediate plans for operations are as follows:

• Convert current natural resource sites into producing assets.
• Identify under-explored mines on existing properties and consider additional under-explored mines for acquisition in the mining districts the Company is currently operating that are either built, permitted or have been idled.
• Continue current exploration and drilling programs and invest resources necessary to discover new ore bodies and open additional mines.

About Jameson Stanford Resources Corp.

Jameson Stanford Resources is focused on developing significant mining claims, mineral leases and excavation rights for projects located in historic mining districts and other sites in central and southwestern Utah. The Company is presently engaged in exploration and development activities in connection with two high-grade copper, gold, silver and base metals properties located in historic mining districts in Beaver County and Juab County, Utah. In addition, Jameson Stanford Resources has acquired excavation rights and special permitting related to deposits of alluvial minerals and silica sand located in Weber County, Utah.

Safe Harbor Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company’s Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

Contact:

Jameson Stanford Resources Corp.
Las Vegas, NV
www.JamesonStanford.com
702-933-0808
IR@JamesonStanford.com

Mission Investor Relations
Atlanta, GA
www.MissionIR.com
404-941-8975
Investors@MissionIR.com

(OCLR) Chairman And CEO Changeover

SAN JOSE, Calif., June 7, 2013 /PRNewswire/ — Oclaro, Inc. (the “Company”) (NASDAQ: OCLR) announced today that Alain Couder, the Company’s chair and chief executive officer, has retired and that the board of directors has named Greg Dougherty, Oclaro board member, as chief executive officer effective immediately.  The Company also announced that Marissa Peterson, Oclaro board member, has been elected as chair.

“On behalf of the entire board, we thank Alain Couder for his contributions to Oclaro,” said Marissa Peterson, chair of the board of directors, Oclaro. “Since joining the company in 2007, Alain has played an important role in transforming the company from a small optical component company called Bookham into an industry leader. As we look ahead, Oclaro’s new CEO, Greg Dougherty brings significant operational experience in the optical industry. We look forward to working closely with Greg as we navigate through the current challenging financial situation.”

Greg Dougherty has served as an Oclaro board member since 2009, and brings to the CEO role substantial leadership, operations, sales, marketing and general management experience in the optical and laser industries, including previous roles as chief operating officer of JDSU, and chief operating officer of SDL.

“Through its rich history of mergers and acquisitions, Oclaro has amassed an extensive technology and product portfolio, and I am honored to join its talented team,” said Greg Dougherty, chief executive officer, Oclaro. “My focus will be to harness those powerful assets to their fullest potential, by accelerating efforts to simplify the company and strengthen our execution; and by focusing on developing and implementing a profitable operating model. My goal is to solidify our position as a leader in the optical industry and to be the preferred supplier to our customers around the world.”

Alain Couder enters retirement after a long and successful career.  Mr. Couder first joined the Company’s predecessor, Bookham, Inc., (Bookham) as CEO in August 2007 and was elected chair of the board in July 2011.  Mr. Couder led Bookham through its merger with Avanex Corporation to create Oclaro and also led the Company through its merger with Opnext, Inc. in July 2012.  Prior to joining Oclaro, Mr. Couder was president and CEO of three private companies, a venture advisor to a venture capital company, the chief operating officer of Agilent Technologies and held various positions over the years with Packard-Bell NEC, Groupe Bulle, Hewlett-Packard and IBM.

“In my career I have had the privilege to work with some of the technology industry’s best and brightest people,” said Alain Couder. “Oclaro has been one of the highlights. With its amazing talent, technology and products, Oclaro can have a substantial impact on the world. As I move on to retirement, I am confident that Oclaro is in good hands under the continued leadership of Greg Dougherty and the exceptional team we have in place.”

Mr. Dougherty, has served as an Oclaro board member since 2009. Prior to Oclaro, Mr. Dougherty served as a director of Avanex Corporation (Avanex) from April 2005 to April 2009, when Avanex and Bookham merged to create Oclaro.  Mr. Dougherty has served as a director of Picarro, Inc., a manufacturer of ultra-sensitive gas spectroscopy equipment using laser-based technology, since October 2002.  He also served as Picarro’s CEO from 2002 through 2003.  Mr. Dougherty served on the board of directors of the Ronald McDonald House at Stanford from January 2004 until 2011.  From February 2001 until September 2002, Mr. Dougherty was the chief operating officer of JDS Uniphase Corporation (JDS), an optical technology company.  Prior to JDS, he was the chief operating officer of SDL, Inc. from March 1997 to February 2001 when they were acquired by JDS. From 1989 to 1997, Mr. Dougherty was the director of product management and marketing of Lucent Technologies Microelectronics in the Optoelectronics Strategic Business Unit.  Mr. Dougherty received a B.Sc. degree in Optics in 1983 from the University of Rochester.

Ms. Peterson who has served as an Oclaro board member since 2011, brings to the chair position her extensive knowledge in the areas of operations, strategy, and customer relations, as well as experience as a senior executive of a large, complex and well-respected technology company. Ms. Peterson was formerly executive vice president, worldwide operations, services and customer advocacy of Sun Microsystems Inc., until her retirement in 2006 after 17 years with the company.  From August 2008 to present, Ms. Peterson has served as a director of Humana Inc., a healthcare provider, and is currently a member of their nominating and corporate governance and organization and compensation committees.  From August 2006 to present, she has served as a director for Ansell Limited, a global public company listed on the Australia Stock Exchange, where she is currently a member of the audit committee and chair of the risk committee.  In addition, Ms. Peterson currently serves as a director of Quantros, Inc. and is a member of their audit committee and chair of the technology committee. She previously served as a director of Supervalu Inc. and the Lucile Packard Children’s Hospital at Stanford, and served on the board of trustees of Kettering University. Ms. Peterson has attained the distinction of being a National Association of Corporate Directors Board Leadership Fellow. Ms. Peterson earned a M.B.A. from Harvard University, and an honorary doctorate of management and a B.S. in mechanical engineering from Kettering University.

About Oclaro

Oclaro, Inc. (NASDAQ: OCLR) is one of the largest providers of lasers and optical components, modules and subsystems for the optical communications, industrial, and consumer laser markets.  The company is a global leader dedicated to photonics innovation, with cutting-edge research and development (R&D) and chip fabrication facilities in the U.S., U.K., Italy, Switzerland, Israel, Korea and Japan. It has in-house and contract manufacturing sites in China, Malaysia and Thailand, with design, sales and service organizations in most of the major regions around the world. For more information, visit http://www.oclaro.com.

Copyright 2013. All rights reserved. Oclaro, the Oclaro logo, and certain other Oclaro trademarks and logos are trademarks and/or registered trademarks of Oclaro, Inc. or its subsidiaries in the U.S. and other countries. All other trademarks are the property of their respective owners. Information in this release is subject to change without notice.

Safe Harbor Statement

This press release contains statements about management’s future expectations, plans or prospects of Oclaro and its business, and together with the assumptions underlying these statements, constitute forward-looking statements for the purposes of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. Such statements can be identified by the fact that they do not relate strictly to historical or current facts and may contain words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “will,” “should,” “outlook,” “could,” “target,” “model,” and other words and terms of similar meaning in connection with any discussion of future events or financial performance. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, such as the factors described in Oclaro’s most recent annual report on Form 10-K, quarterly report on Form 10-Q and other documents we periodically file with the SEC. The forward-looking statements included in this announcement represent Oclaro’s view as of the date of this announcement. Oclaro anticipates that subsequent events and developments may cause Oclaro’s views and expectations to change. Oclaro specifically disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this announcement.

(HCKT) 2013 Best Practices Conference: “Borderless Business”

As economies around the world become more integrated, understanding the optimal way to operate globally has become a driving force. How companies are addressing the opportunities and challenges of today’s global economy was the focus of The Hackett Group’s 2013 North American Best Practices Conference, “Borderless Business: Integrating the Enterprise for Sustainable Success,” held in Miami May 20-22, 2013.

The Hackett Group (NASDAQ:HCKT), a global strategic business advisory and operations improvement consulting firm, is a leader in best practice advisory, business benchmarking, and transformation consulting services including strategy and operations, working capital management, and globalization advice.

This year’s best practices conference brought together speakers from 17 of the world’s most successful companies, including CEOs, CFOs, CIOs, and leaders in procurement, human resources, and global business services from: Becton, Dickinson and Company; Citigroup; Coca Cola Refreshments USA; Cytec Industries; FedEx; Fidelity Investments; General Electric; General Mills; Hertz; Kimberly-Clark; Kronos; Lennox International; Meritor; MetLife; Office Depot; SAP AG; and TE Connectivity. In addition nine companies served as sponsors for The Hackett Group conference: Cadency, a product of Trintech; Coupa Software; Genpact Limited; HP; Invest Lithuania; Kronos; Open Scan; SAP; and Zycus.

The invitation-only event, which was attended by over 200 senior-level executives from the world’s most respected brands, also featured The Hackett Group latest insights on the strategies and tactics being deployed by the highest performing global companies.

At the conference, The Hackett Group also offered an update and live demonstration of The Hackett Group’s Performance Exchange^™, a new automated measurement dashboard designed to accelerate companies’ journeys to world-class performance. The Hackett Group Performance Exchange is a breakthrough performance intelligence solution that automatically extracts data from ERP systems and benchmarks results to produce actionable insights – faster and at a fraction of the cost and effort involved in any benchmarking alternative or building a custom solution.

“Today’s business world is all about transcending borders, and the accelerating flow of ideas, resources, capital, and goods,” explained The Hackett Group Chairman & Chief Executive Officer Ted Fernandez.”The increasingly competitive global marketplace has reduced the interval between seeing an opportunity – or threat – and making the operational changes necessary to respond to it effectively. As a result, information and operational expectations have necessitated one global view of your customers, your supply chain, your operations, your financials and your talent.

“At The Hackett Group’s 2013 North American Best Practices Conference, we offered an opportunity to learn how the world’s most successful companies are adapting to the opportunities and challenges of operating globally,” said Mr. Fernandez.

About The Hackett Group

The Hackett Group (NASDAQ: HCKT), a global strategic business advisory and operations improvement consulting firm, is a leader in best practice advisory, business benchmarking, and transformation consulting services including strategy and operations, working capital management, and globalization advice.

Utilizing best practices and implementation insights from more than 7,500 benchmarking studies, executives use The Hackett Group’s empirically-based approach to quickly define and implement initiatives that enable world-class performance. Through its REL group, The Hackett Group offers working capital solutions focused on delivering significant cash flow improvements. Through its Archstone Consulting group, The Hackett Group offers Strategy & Operations consulting services in the Consumer and Industrial Products, Pharmaceutical, Manufacturing, and Financial Services industry sectors. Through its Hackett Technology Solutions group, The Hackett Group offers business application consulting services that help maximize returns on IT investments. The Hackett Group has completed benchmark studies with over 2,800 major corporations and government agencies, including 97% of the Dow Jones Industrials, 86% of the Fortune 100, 90% of the DAX 30 and 48% of the FTSE 100.

More information on The Hackett Group is available: by phone at (770) 225-7300; by e-mail at info@thehackettgroup.com.

Ocean Power (OPTT) Announces Oregon-Based Regional Representation

PENNINGTON, N.J., June 7, 2013 (GLOBE NEWSWIRE) — Ocean Power Technologies, Inc. (Nasdaq:OPTT) (“OPT”, or “the Company”), a leading wave energy technology company, today announced that it has engaged consultant Kevin Watkins to serve as its Pacific Northwest Representative. OPT is planning for deployment of a Mark 3 PowerBuoy^® wave energy conversion system off the coast of Oregon, and Mr. Watkins will provide support to this process as well as work with interested local groups and stakeholders.

Charles F. Dunleavy, Chief Executive Officer of OPT, said, “We are very happy to have the assistance of Kevin, as we progress with our business activities in Oregon. His career experience with both conventional and renewable energy is a key asset, and he has worked in the past with many of the groups interested in OPT’s wave energy project. Living in Oregon, Kevin will be a vital, local link to those stakeholders. His role will include communications, community outreach, and liaison with local regulatory groups.”

Kevin Watkins has worked in the electric power industry for over 30 years. He was the Engineering Vice President at PNGC Power for 15 years where he coordinated power generation operations and information technology activities required to support power scheduling operations.

“I am excited to work with OPT on this ‘first of its kind’ energy generation project for the Pacific Northwest,” said Kevin Watkins. “I have been involved with alternative and emerging electricity generation technologies for several years and ocean wave energy has the potential to provide significant value to the region.” While at PNGC Power, Mr. Watkins also directed implementation of a Smart Grid Investment Grant awarded to PNGC Power and served on technical review and evaluation committees for the Northwest Power Planning Council and the State of Oregon. He is a registered Professional Engineer.

About Ocean Power Technologies

Ocean Power Technologies, Inc. (Nasdaq:OPTT) is a pioneer in wave-energy technology that harnesses ocean wave resources to generate reliable and clean and environmentally-beneficial electricity. OPT has a strong track record in the advancement of wave energy and participates in an estimated $150 billion annual power generation equipment market. OPT’s proprietary PowerBuoy® system is based on modular, ocean-going buoys that capture and convert predictable wave energy into clean electricity. The Company is widely recognized as a leading developer of on-grid and autonomous wave-energy generation systems, benefiting from over 15 years of in-ocean experience. OPT is headquartered in Pennington, New Jersey, USA with an office in Warwick, UK and operations in Melbourne and Perth, Australia. More information can be found at www.oceanpowertechnologies.com.

Forward-Looking Statements

This release may contain “forward-looking statements” that are within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the Company’s current expectations about its future plans and performance, including statements concerning the impact of marketing strategies, new product introductions and innovation, deliveries of product, sales, earnings and margins. These forward-looking statements rely on a number of assumptions and estimates which could be inaccurate and which are subject to risks and uncertainties. Actual results could vary materially from those anticipated or expressed in any forward-looking statement made by the Company. Please refer to the Company’s most recent Form 10-K and subsequent filings with the Securities and Exchange Commission for a further discussion of these risks and uncertainties. The Company disclaims any obligation or intent to update the forward-looking statements in order to reflect events or circumstances after the date of this release.

CONTACT: Ocean Power Technologies, Inc.
         Charles F. Dunleavy, Chief Executive Officer
         Telephone: +1 609 730 0400

         Kevin Watkins
         kwatkinspdx@gmail.com
         Telephone:  +1 971 404 4859

Conn’s, Inc. (CONN) Reports Results for the Quarter Ended April 30, 2013

Conn’s, Inc. (NASDAQ:CONN), a specialty retailer of home appliances, furniture, mattresses, consumer electronics and provider of consumer credit, today announced its results for the quarter ended April 30, 2013.

Significant items for the first quarter of fiscal 2014 include:

• Net income equaled $22.2 million, $10.6 million above last year;
• Earnings per diluted share rose to $0.61 from $0.35 per share a year ago on a 10.8% increase in diluted shares outstanding;
• Consolidated revenues were $251.1 million, up 25.0% over the prior-year quarter;
• Same store sales rose 16.5% from the prior-year period, on top of same store sales growth of 17.8% last year;
• Retail gross margin was 40.3% for the quarter, an increase year-over-year of 660 basis points;
• Retail segment operating income was $27.3 million, $16.5 million above the level reported in the prior-year period; and
• Credit segment operating income totaled $11.7 million, an increase of 5.5% from the prior-year quarter.

“We are pleased to again report record net income. Over the past six quarters, our operations have delivered year-over-year expansion in both same store sales and retail margins. With the addition of new stores and update of existing stores, furniture and mattress sales growth is accelerating. Furniture and mattress sales were up over 70% from last year and accounted for 26% of our total product sales in the current period,” stated Theodore M. Wright, the Company’s Chairman and CEO. “May 2013 same store sales rose 18% with same store sales of consumer electronics up 4%.”

Retail Segment Results

Revenues for the quarter ended April 30, 2013 increased $42.6 million, or 25.5%, over the prior-year period to $209.8 million. The year-over-year growth was driven by the significant expansion in same store sales and the five Conn’s HomePlus^TM stores opened in fiscal 2013. Two new stores opened on April 26, 2013. As of quarter end, 22 existing stores were updated to the Conn’s HomePlus format.

The following table presents net sales by category and changes in net sales for the current and prior-year quarter:

The following provides a summary of items influencing the Company’s major product category performance during the quarter, compared to the prior-year period:

• Home appliance average selling price rose 14.6% and unit volume increased 3.8%. Laundry sales increased 25.8%, refrigeration sales were up 16.2% and cooking sales rose 19.4%;
• Furniture unit sales increased 81.6% and the average selling price was down slightly;
• Mattress unit volume increased 33.6% and average selling price was up 19.7%;
• Same store sales of consumer electronics improved through the quarter. In April, same store sales were up 5.9%; and
• Tablet sales increased 218.0% and computer sales were up 16.2%.

Retail gross margin was 40.3% for the quarter ended April 30, 2013, compared to 33.7% in the prior-year period. Certain of the Company’s vendors provide higher promotional assistance during the first quarter of each fiscal year which benefited retail gross margin by approximately 150 basis points in both periods. Margin improvement was reported in each of the product categories – reflecting the benefit of the sale of higher price-point, higher-margin goods and realization of sourcing opportunities. Product margin on furniture and mattress sales rose 6.1 percentage points from the prior-year period to 48.3% of sales. Furniture and mattress sales were 25.7% of total product revenue in the current period and generated 34.8% of the total product gross profit.

Credit Segment Results

Revenues were $41.3 million for the current quarter, up 22.6% from the prior-year period. The revenue increase resulted from an increase in the average receivable portfolio balance outstanding. The portfolio balance rose to $773.4 million at April 30, 2013, from $635.2 million in the prior-year period, due to higher retail sales volumes and credit penetration over the past year. The portfolio interest and fee income yield was 18.0% for the three months ended April 30, 2013, relatively consistent with the prior-year period, but down 70 basis points sequentially as a result of increased short-term, no-interest financing.

Provision for bad debts was $13.8 million for the quarter ended April 30, 2013, an increase of $4.8 million from the prior-year period. This additional provision was driven primarily by the substantial year-over-year growth in the average receivable portfolio balance outstanding, which includes an increase of $31.9 million during the current quarter.

Additional information on the credit portfolio and its performance may be found in the table included within this press release and in the Company’s Form 10-Q to be filed with the Securities and Exchange Commission.

Capital and Liquidity

In March of 2013, the Company received an additional $40 million of lender commitments under its asset-based loan facility increasing total commitments under the facility to $585 million. During the first quarter, the Company also repaid the remaining asset-backed notes. In connection with the early repayment of the asset-backed notes, the Company accelerated the amortization of deferred financing cost resulting in an additional $0.4 million of interest expense.

The Company’s improved operating performance and credit portfolio velocity allowed it to internally fund the growth in its credit portfolio as well as capital expenditures. As of April 30, 2013, the Company had $293.7 million of borrowings outstanding under its asset-based loan facility. Additionally, the Company had $244.6 million of immediately available borrowing capacity as of April 30, 2013, and an additional $45.3 million that could become available upon increases in eligible inventory and customer receivable balances under the borrowing base.

Outlook and Guidance

The Company increased earnings guidance for the fiscal year ending January 31, 2014, to diluted earnings per share of $2.50 to $2.65 on an adjusted basis. The following expectations were considered in developing the guidance for the full year:

• Same stores sales up 8% to 13%;
• New store openings of between 10 and 12;
• Retail gross margin between 37.5% and 38.5%;
• An increase in the credit portfolio balance;
• Credit portfolio interest and fee yield of between 18.0% and 18.3%, reflecting a higher proportion of the portfolio balance represented by no-interest credit programs than in fiscal 2013;
• Provision for bad debts of between 6.5% and 7.0% of the average portfolio balance outstanding;
• Selling, general and administrative expense of between 28.0% and 29.0% of total revenues; and
• Diluted shares outstanding of approximately 37.0 million.

Conference Call Information

Conn’s, Inc. will host a conference call and audio webcast on Thursday, June 6, 2013, at 10:00 A.M. CT, to discuss its earnings and operating performance for the quarter. A link to the live webcast, which will be archived for one year, and slides to be referred to during the call will be available at ir.Conns.com. Participants can join the call by dialing 877-754-5302 or 678-894-3020.

About Conn’s, Inc.

Conn’s is a specialty retailer currently operating 70 retail locations in Texas (58), Louisiana (6), Oklahoma (3), New Mexico (2) and Arizona (1). The Company’s primary product categories include:

• Home appliance, including refrigerators, freezers, washers, dryers, dishwashers and ranges;
• Furniture and mattress, including furniture and related accessories for the living room, dining room and bedroom, as well as both traditional and specialty mattresses;
• Consumer electronic, including LCD, LED, 3-D and plasma televisions, Blu-ray players, home theater and video game products, camcorders, digital cameras, and portable audio equipment; and
• Home office, including computers, tablets, printers and accessories.

Additionally, the Company offers a variety of products on a seasonal basis, including lawn and garden equipment, room air conditioners and outdoor furniture. Unlike many of its competitors, the Company provides flexible in-house credit options for its customers, in addition to third-party financing programs and third-party rent-to-own payment plans.

This press release contains forward-looking statements that involve risks and uncertainties. Such forward-looking statements include information concerning our future financial performance, business strategy, plans, goals and objectives. Statements containing the words “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “should,” or the negative of such terms or other similar expressions are generally forward-looking in nature and not historical facts. Although we believe that the expectations, opinions, projections, and comments reflected in these forward-looking statements are reasonable, we can give no assurance that such statements will prove to be correct. A wide variety of potential risks, uncertainties, and other factors could materially affect our ability to achieve the results either expressed or implied by our forward-looking statements including, but not limited to: general economic conditions impacting our customers or potential customers; our ability to continue existing or offer new customer financing programs; changes in the delinquency status of our credit portfolio; higher than anticipated net charge-offs in the credit portfolio; the success of our planned opening of new stores and the updating of existing stores; technological and market developments and sales trends for our major product offerings; our ability to fund our operations, capital expenditures, debt repayment and expansion from cash flows from operations, borrowings from our revolving credit facility, and proceeds from accessing debt or equity markets; and the other risks detailed from time-to-time in our SEC reports, including but not limited to, our Annual Report on Form 10-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except as required by law, we are not obligated to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

Ciena (CIEN) Reports Fiscal Second Quarter 2013 Financial Results

Ciena^® Corporation (NASDAQ: CIEN), the network specialist, today announced unaudited financial results for its fiscal second quarter ended April 30, 2013.

For the fiscal second quarter 2013, Ciena reported revenue of $507.7 million.

On the basis of generally accepted accounting principles (GAAP), Ciena’s net loss for the fiscal second quarter 2013 was $(27.1) million, or $(0.27) per common share, which compares to a GAAP net loss of $(27.8) million, or $(0.28) per common share, for the fiscal second quarter 2012.

Ciena’s adjusted (non-GAAP) net income for the fiscal second quarter 2013 was $2.2 million, or $0.02 per common share, which compares to an adjusted (non-GAAP) net income of $3.7 million, or $0.04 per common share, for the fiscal second quarter 2012.

“We have designed Ciena to take advantage of the fundamental shift in network architecture driven by changing end-user demands, and our strong quarterly and first half of 2013 performance are a direct result of that strategy. Our unique ability to provide customers convergence, automation, openness and software intelligence positions us to lead the industry in this shift,” said Gary B. Smith, president and CEO of Ciena. “These dynamics are creating new opportunities that we believe will enable us to continue making progress toward our long-term financial goals.”

Fiscal Second Quarter 2013 Performance Summary

The tables below (in millions, except percentage data) provide comparisons of certain quarterly results to prior periods, including sequential quarterly and year-over-year changes. A reconciliation between the GAAP and adjusted (non-GAAP) measures contained in this release is included in Appendix A.

Additional Performance Metrics for Fiscal Second Quarter 2013

• Non-U.S. customers contributed 43% of total revenue
• Two customers accounted for greater than 10% of revenue and represented 31.3% of total revenue
• Cash and investments totaled $456.5 million
• Cash flow from operations totaled $44.9 million
• Free cash flow totaled $35.6 million
• Average days’ sales outstanding (DSOs) were 75
• Accounts receivable balance was $421.0 million
• Inventories totaled $248.1 million, including:
  • Raw materials: $49.9 million
  • Work in process: $9.7 million
  • Finished goods: $145.1 million
  • Deferred cost of sales: $84.2 million
  • Reserve for excess and obsolescence: $(40.8) million
• Product inventory turns were 3.9
• Headcount totaled 4,546

Business Outlook for Fiscal Third Quarter 2013

Statements relating to business outlook are forward-looking in nature and actual results may differ materially. These statements should be read in the context of the Notes to Investors below.

Ciena expects fiscal third quarter 2013 financial performance to include:

• Revenue in the range of $515 to $545 million
• Adjusted (non-GAAP) gross margin in the low 40s percent range
• Adjusted (non-GAAP) operating expense in the mid $190s million range

Live Web Broadcast of Unaudited Fiscal Second Quarter 2013 Results

Ciena will host a discussion of its unaudited fiscal second quarter 2013 results with investors and financial analysts today, Thursday, June 6, 2013 at 8:30 a.m. (Eastern). The live broadcast of the discussion will be available via Ciena’s homepage at http://www.ciena.com/. To accompany its live broadcast, Ciena has posted to the Investor Relations page of its website at: www.ciena.com/investors a presentation for investors that includes certain highlighted information relating to this quarter and certain historical results of operation. An archived transcript of the discussion will be available shortly following the conclusion of the live broadcast on the Investor Relations page of Ciena’s website at: www.ciena.com/investors.

Notes to Investors

Forward-looking statements. This press release contains certain forward-looking statements that involve risks and uncertainties. These statements are based on current expectations, forecasts, assumptions and other information available to the Company as of the date hereof. Forward-looking statements include statements regarding Ciena’s expectations, beliefs, intentions or strategies regarding the future and can be identified by forward-looking words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “should,” “will,” and “would” or similar words. Forward-looking statements in this release include Ciena’s business outlook for the fiscal third quarter of 2013 as well as: “We have designed Ciena to take advantage of the fundamental shift in network architecture driven by changing end-user demands, and our strong quarterly and first half of 2013 performance are a direct result of that strategy.”; “Our unique ability to provide customers convergence, automation, openness and software intelligence positions us to lead the industry in this shift.”; “These dynamics are creating new opportunities that we believe will enable us to continue making progress toward our long-term financial goals.”

Ciena’s actual results, performance or events may differ materially from these forward-looking statements made or implied due a number of risks and uncertainties relating to Ciena’s business, including: the effect of broader economic and market conditions on our customers and their business; changes in network spending or network strategy by large communication service providers; seasonality and the timing and size of customer orders, including our ability to recognize revenue relating to such sales; the level of competitive pressure we encounter; the product, customer and geographic mix of sales within the period; supply chain disruptions and the level of success relating to efforts to optimize Ciena’s operations; changes in foreign currency exchange rates affecting revenue and operating expense; and the other risk factors disclosed in Ciena’s Report on Form 10-Q filed with the Securities and Exchange Commission on March 13, 2013. Ciena assumes no obligation to update any forward-looking information included in this press release.

Non-GAAP Presentation of Quarterly Results. This release includes non-GAAP measures of Ciena’s gross profit, operating expense, income (loss) from operations, net income (loss) and net income (loss) per share. In evaluating the operating performance of Ciena’s business, management excludes certain charges and credits that are required by GAAP. These items share one or more of the following characteristics: they are unusual and Ciena does not expect them to recur in the ordinary course of its business; they do not involve the expenditure of cash; they are unrelated to the ongoing operation of the business in the ordinary course; or their magnitude and timing is largely outside of Ciena’s control. Management believes that the non-GAAP measures below provide management and investors useful information and meaningful insight to the operating performance of the business. The presentation of these non-GAAP financial measures should be considered in addition to Ciena’s GAAP results and these measures are not intended to be a substitute for the financial information prepared and presented in accordance with GAAP. Ciena’s non-GAAP measures and the related adjustments may differ from non-GAAP measures used by other companies and should only be used to evaluate Ciena’s results of operations in conjunction with our corresponding GAAP results. To the extent not previously disclosed in a prior Ciena financial results press release, Appendix A to this press release sets forth a complete GAAP to non-GAAP reconciliation of the non-GAAP measures contained in this release.

About Ciena

Ciena is the network specialist. We collaborate with customers worldwide to unlock the strategic potential of their networks and fundamentally change the way they perform and compete. Ciena leverages its deep expertise in packet and optical networking and distributed software automation to deliver solutions in alignment with OPⁿ, its approach for building open next-generation networks. We enable a high-scale, programmable infrastructure that can be controlled and adapted by network-level applications, and provide open interfaces to coordinate computing, storage and network resources in a unified, virtualized environment. Investors are encouraged to review the Investors section of our website at www.ciena.com/investors, where we routinely post press releases, SEC filings, recent news, financial results, other announcements and, from time to time, exclusively post material information as with the other disclosure channels that we use.

The adjusted (non-GAAP) measures above and their reconciliation to Ciena’s GAAP results for the periods presented reflect adjustments relating to the following items:

• Share-based compensation expense – a non-cash expense incurred in accordance with share-based compensation accounting guidance.
• Amortization of intangible assets – a non-cash expense arising from the acquisition of intangible assets, principally developed technologies and customer-related intangibles, that Ciena is required to amortize over its expected useful life.
• Acquisition and integration costs – reflects transaction expense, and consulting and third party service fees associated with the acquisition of the Nortel MEN Business and the integration of this business into Ciena’s operations.
• Restructuring costs – costs incurred as a result of restructuring activities (or in the case of recoveries, previous restructuring activities) taken to align resources with perceived market opportunities.
• Non-cash interest expense – a non-cash debt discount expense amortized as interest expense during the term of Ciena’s 4.0% senior convertible notes due December 15, 2020 relating to the required separate accounting of the equity component of these convertible notes.
• Change in fair value of embedded redemption feature – a non-cash unrealized gain or loss reflective of a mark to market fair value adjustment of an embedded derivative related to the redemption feature of Ciena’s outstanding 4.0% senior convertible notes due March 15, 2015.

Cardium (CXM) Initial Voting Results And Temporary Adjournment of Annual Meeting

SAN DIEGO, June 6, 2013 /PRNewswire/ — Cardium Therapeutics (NYSE MKT: CXM) held its Annual Meeting of Stockholders earlier today.  The proposals considered at the Annual Meeting are described in detail in the Company’s definitive proxy statement for the Annual Meeting as filed with the Securities and Exchange Commission on April 29, 2013.

At today’s annual meeting, stockholders considered and approved the following matters:  (a) the re-election of the Company’s Class I Directors, which included Edward W. Gabrielson, M.D. and Lon E. Otremba, each to serve for a three-year term; (b) the compensation paid to the Company’s named executive officers; (c) establishment of a three-year advisory say on pay frequency; (d) the sale of certain Series A preferred stock; and (e) ratification of the selection of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2013.

The Company temporarily adjourned the meeting to allow for additional time for stockholders to vote on two remaining proposals related to a proposed reverse stock split and a charter amendment, which were favored by a majority of shares voted but which also require a majority of all outstanding shares, including unvoted shares.  Of the votes that were cast prior to today’s meeting, approximately 61% were voted in favor of the reverse stock split and approximately 66% were voted in favor of the increase in the number of authorized shares.  However, both proposals also require the affirmative vote of a majority of the issued and outstanding shares of Cardium’s common stock, which includes more than 38 million shares that remain unvoted. The adjournment will allow for additional stockholders to vote on these proposals.  The annual meeting will reconvene on June 21, 2013 at 9:00 a.m., Pacific Time, at the same location.

“We are encouraged by the favorable support that we have received to date from our stockholders who have voted in favor of all of the proposals recommended by the Board of Directors as described in our proxy,” stated Christopher J. Reinhard, Chairman and CEO of Cardium. As previously reported, Glass Lewis and ISS, the leading independent proxy and corporate governance advisory firms, have also recommended in favor of all of the proposals, including the stock split and charter amendment, and given the importance of these issues, we want to make sure that all stockholders have sufficient time to vote their preferences.  We encourage stockholders who have not yet executed a proxy to do so.  This will help save us further solicitation costs on the proposals and ensure that they are represented.”

Proposal five gives Cardium’s Board of Directors the authority to effect a reverse split of the Company’s outstanding common stock.  Proposal six provides for an amendment to the Company’s Amended and Restate Certificate of Corporation – which amendment would ONLY be entered in the event that Proposal 5 is not approved – and which would allow for the increase in the number of authorized share of common stock of the Company from 200,000,000 to 400,000,000.

During the period of the adjournment, Cardium will continue to solicit proxies from its stockholders with respect to the remaining two proposals.  Stockholders who have already voted need not take any action on the proposal, although they may change their vote for the Proposals by executing a new proxy, revoking a previously given proxy as set forth in Cardium’s proxy statement, or by calling 888-219-8320.

Cardium’s proxy statement and any other materials filed by the Company with the SEC can be obtained free of charge at the SEC’s website at www.sec.gov or from the Company’s website at www.cardiumthx.com.  Only stockholders who held the Company’s common stock as of the record date of April 26, 2013 are eligible to vote.

About Cardium

Cardium is an asset-based health sciences and regenerative medicine company focused on the acquisition and strategic development of innovative products and businesses with the potential to address significant unmet medical needs and having definable pathways to commercialization, partnering or other economic monetizations. Cardium’s current portfolio includes the Tissue Repair Company, Cardium Biologics, and the Company’s newly-acquired To Go Brands^® nutraceutical business. The Company’s lead commercial product, Excellagen^® topical gel for wound care management, has received FDA clearance for marketing and sale in the United States.  Cardium’s lead clinical development product candidate Generx^® is a DNA-based angiogenic biologic intended for the treatment of patients with myocardial ischemia due to coronary artery disease. To Go Brands^® develops, markets and sells dietary supplements through established regional and national retailers.  In addition, consistent with its capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities. For more information, visit www.cardiumthx.com.

Forward-Looking Statements 

Except for statements of historical fact, the matters discussed in this press release and in the investor presentation available on the Company’s website and to be presented following the annual meeting of stockholders are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from expectations. For example, there is no assurance that the company will obtain sufficient additional votes in connection with the adjourned meeting or that the remaining proposals will be approved at the adjourned meeting or at any subsequent meeting, that planned product development efforts and clinical studies can be performed in an efficient and effective manner; that results or trends observed in one clinical study or procedure will be reproduced in subsequent studies or in actual use; that new clinical studies will be successful or will lead to approvals or clearances from health regulatory authorities, or that approvals in one jurisdiction will help to support studies or approvals elsewhere; that certain elements of the preferred stock financing or other matters submitted for approval by stockholders will be approved by stockholders; that the Company will satisfy the requirements of its compliance plan and will otherwise continue to satisfy the listing requirements of its exchange or that its shares can continue to be listed on a national exchange; that we can raise sufficient capital from partnering, monetization or other fundraising transactions to maintain our stock exchange listing or adequately fund ongoing operations; that the Company can attract suitable commercialization partners for our products or that we or partners can successfully commercialize them; that our product or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive or blocked by third party proprietary rights or other means; that the products and product candidates referred to in this report or in our other reports will be successfully commercialized and their use reimbursed, or will enhance our market value; that our To Go Brands business can be successfully integrated and expanded; that new product opportunities or commercialization efforts will be successfully established; that third parties on whom we depend will perform as anticipated; that the preferred stock offering can be completed as proposed or that the Company will not be adversely affected by risks and uncertainties that could impact our operations, business or other matters, as described in more detail in our filings with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

Avanir (AVNR) Accelerates Development Path for AVP-786 After FDA Pre-IND Success

Expedited Development Path will Allow Seamless Integration of AVP-786 into ongoing Clinical Programs

ALISO VIEJO, Calif., June 5, 2013 /PRNewswire/ — Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the U.S. Food and Drug Administration (FDA) has agreed to an expedited development pathway for their next-generation compound, AVP-786, requiring only a limited pre-clinical package as part of the Investigational New Drug (IND) application.  Upon completion of these preclinical studies the company intends to proceed directly into human clinical trials.

(Logo: http://photos.prnewswire.com/prnh/20130207/LA55901LOGO )

“We are very pleased with the outcome of our recent meeting with the Division of Neurology of the FDA,” said Joao Siffert, MD, Avanir’s chief scientific officer.  “Avanir will be allowed to reference the extensive data generated during AVP-923 development programs in support of the AVP-786 IND and subsequent new drug application. This has the potential to substantially reduce the cost and time to market.  We anticipate that we will be able to seamlessly integrate AVP-786 into our ongoing development programs in neuropathic pain, agitation in Alzheimer’s disease and levodopa induced dyskinesia in Parkinson’s disease.”

About AVP-786
AVP-786 is a novel investigational drug product consisting of a combination of deuterium modified dextromethorphan (a new chemical entity or NCE) and ultra-low dose quinidine, used as a metabolic inhibitor. Incorporation of deuterium into specific positions of the dextromethorphan molecule strengthens the chemical bonds and reduces susceptibility to enzyme cleavage and first pass metabolism, but without altering its pharmacology. AVP-786 is an investigational drug not approved by the FDA.

About AVP-923
AVP-923 is a combination of two well-characterized compounds, the active CNS ingredient dextromethorphan hydrobromide (an uncompetitive NMDA receptor antagonist and sigma-1 receptor agonist) plus low-dose quinidine sulfate (a CYP2D6 enzyme inhibitor), which serves to increase the bioavailability of dextromethorphan. AVP-923 is being studied in several ongoing clinical trials including agitation in Alzheimer’s disease, neuropathic pain in Multiple Sclerosis, levodopa-induced dyskinesia in Parkinson’s disease, and behavioral symptoms of autism. AVP-923 for the above investigational uses has not been approved by the FDA.

About Avanir Pharmaceuticals, Inc.
Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about Avanir, please visit www.avanir.com.

AVANIR^® is a trademark or registered trademark of Avanir Pharmaceuticals, Inc. in the United States and other countries.

^©2013 Avanir Pharmaceuticals, Inc. All Rights Reserved.

Forward Looking Statements
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding Avanir’s plans, potential opportunities, financial or other expectations, projections, goals objectives, milestones, strategies, market growth, timelines, legal matters, product pipeline, clinical studies, product development and the potential benefits of its commercialized products and products under development are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with, the market demand for and acceptance of Avanir’s products domestically and internationally, research, development and commercialization of new products domestically and internationally, including the risks and uncertainties associated with meeting the objectives of the study of AVP-786, including, but not limited to, risks relating to the successful development of this investigational drug, delays or failures in enrollment, obtaining additional indications for commercially marketed products domestically and internationally, obtaining and maintaining regulatory approvals domestically and internationally, and other risks detailed from time to time in the Company’s most recent Annual Report on Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Avanir Investor & Media Contact
Ian Clements, PhD
ir@avanir.com
+1 (949) 389-6700

Peter J. Carbonaro Joins Atossa Genetics (ATOS) as Senior VP of Operations

SEATTLE, WA — (Marketwired) — 06/05/13 — Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, announced today that Peter J. Carbonaro has joined the Company as Senior Vice President of Operations, a newly created position. Mr. Carbonaro’s primarily focus and responsibilities include regulatory, quality, manufacturing, supply chain, IT, Facilities and Human Resources. He reports to Dr. Steven Quay, Chairman, CEO & President.

A veteran diagnostic/medical device/biotechnology industry decision maker, Mr. Carbonaro brings more than 30 years’ experience in process development, supply chain and manufacturing. This includes expertise in product development, technology transfer, manufacturing and supply chain at a number of prominent companies including Gilead Sciences and Hoffmann LaRoche as well as several early stage companies.

“The Company is very fortunate to have Peter Carbonaro join us as at this pivotal time as we continue to ramp up sales and manufacturing of our ForeCYTE Breast Health Test,” said Dr. Quay. “Peter’s extensive industry experience and in-depth operations and manufacturing expertise will be invaluable in helping us make the ForeCYTE test available to millions of women across America.”

“Atossa Genetics has the potential to change the way we think about breast cancer risk assessment and prevention and I am excited to join the Atossa team to help make the ForeCYTE test and other products and services developed by the Company become the standard of care,” said Mr. Carbonaro. “I am honored to join the Atossa team to drive our success for the benefit of women in the fight against breast cancer.”

Prior to joining Atossa Genetics, Mr. Carbonaro (54) served as Vice President, Operations, at Ondine Biomedical, Inc. from 2011 to 2013. From 2006 to 2011, Mr. Carbonaro served in increasingly responsible positions at Gilead Sciences, Inc., including Director of Manufacturing in Seattle, Washington; Director of Manufacturing in Ireland; Director of Global Operational Excellence, Pharmaceutical Manufacturing and Senior Director, Pharmaceutical Manufacturing. Earlier, Mr. Carbonaro served from 2001 to 2006 as Senior Director of Manufacturing for Corus Pharma, which was acquired by Gilead Sciences in 2006. From 1997 to 2001, Mr. Carbonaro was Vice President of Operations at Bartel, Inc., which was later acquired by Trinity Biotech.

Mr. Carbonaro began his career at Roche Diagnostic Systems, Inc., Belleville, New Jersey, where he served as Production Manager, Senior Group Leader and Associate Scientist. Mr. Carbonaro also served as Vice President of Operations and Director of Operations at Aprogenix, Inc., based in Houston, prior to joining Bartels.

Mr. Carbonaro holds an MBA in Organizational Behavior from Iona College and a BS degree in biology from Siena College.

On June 3, 2013, and as an inducement to cause Mr. Carbonaro to join the Company, he was awarded an option to purchase a total of 250,000 shares of common stock of the Company, par value $0.001 per share, 163,000 of which are outside the Company’s 2010 Stock Option and Incentive Plan. The stock option has an exercise price equal to $4.58 per share, the fair market value on the grant date and vests over a four-year period from his commencement of service. This stock option was granted as an inducement material to Mr. Carbonaro’s entering into employment with the Company and is being reported in accordance with NASDAQ Listing Rule 5635(c)(4).

About Atossa Genetics, Inc.

Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, based in Seattle, WA, is focused on preventing breast cancer through the commercialization of patented, FDA-designated Class II diagnostic medical devices and patented, laboratory developed tests (LDT) that can detect precursors to breast cancer up to eight years before mammography.

The National Reference Laboratory for Breast Health (NRLBH), a wholly owned subsidiary of Atossa Genetics, Inc., is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, Washington.

For additional information on Atossa and the ForeCYTE test, please visit www.atossagenetics.com. For additional information on the National Reference Laboratory for Breast Health, please visit www.nrlbh.com.

Forward-Looking Statements

Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, regulatory clearances, responses to regulatory matters, Atossa’s ability to continue to manufacture and sell its products, the efficacy of Atossa’s products and services, the market demand for and acceptance of Atossa’s products and services, performance of distributors and other risks detailed from time to time in Atossa’s filings with the Securities and Exchange Commission, including without limitation its registration statement on Form S-1 filed April 5, 2013, and periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact:

Atossa Genetics, Inc.
Kyle Guse
CFO and General Counsel
(O) 800-351-3902
Email Contact

Matthew D. Haines (Investors)
Managing Director
MBS Value Partners
(O) 212-710-9686
Email Contact

Hallwood Group (HWG) Announces Merger Agreement

DALLAS, June 5, 2013 /PRNewswire/ — The Hallwood Group Incorporated (NYSE MKT: HWG), a Delaware corporation (the “Company”), today announced that on June 4, 2013 the Company, Hallwood Financial Limited, a corporation organized under the laws of the British Virgin Islands (“Parent”), and HFL Merger Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent (“Merger Sub”), entered into an Agreement and Plan of Merger (the “Merger Agreement”). The Merger Agreement provides that, upon the terms and subject to the conditions set forth in the Merger Agreement, Merger Sub will merge with and into the Company (the “Merger”), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent.  Parent is controlled by Anthony J. Gumbiner, Chairman and Chief Executive Officer of the Company and Parent currently owns 1,001,575, or 65.7%, of the issued and outstanding shares of common stock, par value $0.10 per share, of the Company (such shares, collectively, the “Company Common Stock,” and, each, a “Share”).

As previously announced, on November 6, 2012, the Company received a proposal from Parent to acquire all of the outstanding shares of Company Common Stock that it does not beneficially own at a cash purchase price of $10.00 per share. On November 7, 2012, at the Company’s regularly scheduled Board of Directors meeting, a special committee, consisting solely of independent and disinterested directors (the “Special Committee”), was formed to consider and negotiate the proposal and to make a recommendation to the Company’s Board of Directors. Subsequently, the Special Committee retained its own independent legal representation and selected and engaged a financial advisor to assist in the review of the proposed transaction.

All of the members of the Board of Directors of the Company other than Anthony J. Gumbiner, acting upon the unanimous recommendation of the Special Committee, have (i) determined that it is in the best interests of the Company and its stockholders (other than Parent and Merger Sub), and declared it advisable, to enter into the Merger Agreement, (ii) approved the execution, delivery and performance of the Merger Agreement and the consummation of the transactions contemplated thereby, including the Merger and (iii) resolved to recommend adoption of the Merger Agreement by the stockholders of the Company;

At the effective time of the Merger, each Share of Company Common Stock outstanding immediately prior to the effective time of the Merger and not already owned by Parent will receive $10.00 in cash, without interest.

Stockholders of the Company will be asked to vote on the adoption of the Merger Agreement at a special stockholders meeting that will be held on a date to be announced. The closing of the Merger is subject to a non-waivable condition that the Merger Agreement be adopted by (i) the affirmative vote of the holders of a majority of the outstanding shares of the Company Common Stock entitled to vote on the adoption of the Merger Agreement, voting together as a single class, and (ii) the affirmative vote of the holders of a majority of the outstanding shares of the Company Common Stock, voting together as a single class, excluding all shares of Company Common Stock owned by Parent, Merger Sub, Mr. Gumbiner or any of their respective affiliates (other than the Company and its subsidiaries), or by any director, officer or other employee of the Company or any of its subsidiaries.

Consummation of the Merger is subject to certain other customary conditions, including, among others, (i) absence of any order or injunction prohibiting the consummation of the Merger, (ii) subject to certain exceptions, the accuracy of representations and warranties with respect to the business of the Company, (iii) each of the Company and Parent having performed their respective obligations pursuant to the Merger Agreement and (iv) the absence of a “Company Material Adverse Effect,” which is defined in the Merger Agreement to include the occurrence of an “Event of Default” under that certain Loan Agreement, dated as of March 30, 2012, among Branch Banking and Trust Company, Brookwood Companies Incorporated, the Company and the other signatories thereto, filed with Securities and Exchange Commission (the “SEC”) as Exhibit 10.20 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2011.

The foregoing description of the Merger Agreement is not a complete description of all of the parties’ rights and obligations under the Merger Agreement and is qualified in its entirety by this reference to the Merger Agreement, which is filed as Exhibit 2.1 on Form 8-K dated June 4, 2013.

In connection with the proposed merger transaction, the Company will file with the SEC and furnish to the Company’s stockholders a proxy statement and other relevant documents. BEFORE MAKING ANY VOTING DECISION, THE COMPANY’S STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT IN ITS ENTIRETY WHEN IT BECOMES AVAILABLE AND ANY OTHER DOCUMENTS TO BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED MERGER OR INCORPORATED BY REFERENCE INTO THE PROXY STATEMENT BECAUSE THOSE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED MERGER AND THE PARTIES TO THE MERGER. The Company’s stockholders will be able to obtain a free copy of documents filed with the SEC at the SEC’s website at http://www.sec.gov. In addition, the Company’s stockholders may obtain a free copy of the Company’s filings with the SEC from the Company’s website at http://www.hallwood.com/hwg/SEC.php or by directing a request to: The Hallwood Group Incorporated, 3710 Rawlins, Suite 1500, Dallas, TX 75219; Attention:  Investor Relations; Phone: (214) 528-5588 or (800) 225-0135.

The Company’s shares trade on the NYSE MKT stock exchange under the symbol of HWG and closed on November 5, 2012 (the day prior to the receipt of the proposal) at $6.00 per share. The Company’s shares closed on June 3, 2013 at $8.05 per share.

This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).  Forward-looking statements generally can be identified by the use of forward-looking terminology, such as “may,” “will,” “would,” “expect,” “intend,” “could,” “estimate,” “should,” “anticipate”, “doubt” “plan” “forecast” or “believe.”  The Company intends that all forward-looking statements be subject to the safe harbors created by these laws.  All statements other than statements of historical information provided herein are forward-looking and may contain information about financial results, economic conditions, trends, and known uncertainties. All forward-looking statements are based on current expectations regarding important risk factors.  Many of these risks and uncertainties are beyond the Company’s ability to control, and, in many cases, the Company cannot predict all of the risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements.  Actual results could differ materially from those expressed in the forward-looking statements, and readers should not regard those statements as a representation by the Company or any other person that the results expressed in the statements will be achieved.  Important risk factors that could cause results or events to differ from current expectations are described in the Company’s annual report on Form 10-K for the year ended December 31, 2012 under Item 1A –”Risk Factors”.  These factors are not intended to be an all-encompassing list of risks and uncertainties that may affect the operations, performance, development and results of the Company’s business.  Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.  The Company undertakes no obligation to release publicly the results of any revisions to these forward-looking statements which may be made to reflect events or circumstances after the date hereof, including without limitation, changes in its business strategy or planned capital expenditures, growth plans, or to reflect the occurrence of unanticipated events, although other risks and uncertainties may be described, from time to time, in the Company’s periodic filings with the SEC.

(KNDI) Co-developed Pure Electric Sedan Approved by Chinese MIIT

Jinhua, China–(Newsfile Corp. – June 5, 2013) – Kandi Technologies Group, Inc. (NASDAQ: KNDI) (the ‘Company’ or ‘Kandi’), today announced that JL7001BEV, the first pure electric sedan jointly developed by Kandi and Geely Automobile Holdings Ltd. (Hong Kong Stock Exchange, Stock Code: 175) (the “Geely”), has been approved by Ministry of Industry and Information Technology of the People’s Republic of China (“MIIT”).

To view an enhanced version of this image, please visit:
http://orders.newsfilecorp.com/files/2079/5563_newsreleaselrgex1x1.jpg

According to No. 27 public announcement of MIIT, Kandi Brand/JL7001BEV model is among the latest vehicles on the lists of “Approved Vehicles (No. 248)” and “Recommended Models for Energy Saving & New Energy Vehicle Demonstration and Promotion in China (No. 45)”. As a result of this approval, the purchaser of such pure electric sedan will now be qualified to receive all levels of national and local subsidies and incentives for EVs.

Mr. Hu Xiaoming, Chairman & CEO of Kandi commented, “Given the MIIT’s latest approval, Kandi and Geely have accomplished a significant progress in their cooperation. We will take advantage of the strength, resources and expertise of both Kandi and Geely to achieve a greater success in manufacturing, R&D and sales of the EV in China.”

About Kandi Technologies Group, Inc.

Kandi Technologies Group, Inc. (NASDAQ: KNDI), headquartered in Jinhua, Zhejiang Province, is engaged in the research and development, manufacturing and sales of various vehicles. Kandi has established itself as the one of the world’s largest manufacturer of pure electric vehicles (EVs), Go-Kart vehicles, and tricycle and utility vehicles (UTVs), among others. More information can be viewed at its corporate website is http://www.kandivehicle.com.

Safe Harbor Statement

This press release contains certain statements that may include “forward-looking statements.” All statements other than statements of historical fact included herein are “forward-looking statements.” These forward-looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including the risk factors discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on the SEC’s website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

Contact:

Kandi Technologies Group, Inc.

China:
Email: IR@kandigroup.com
Phone: 86-579-82239856

U.S.A.:
Email: IR@kandigroup.com
Phone: 1-212-551-3610

(HOTR) Sending Lucky Contest Winner Guest to Vegas for Hooters International Swimsuit Pageant

CHARLOTTE, NC–(Marketwired – June 05, 2013) –  Chanticleer Holdings, Inc. (NASDAQ: HOTR) (“Chanticleer Holdings” or the “Company”), a minority owner in the privately held parent company of the Hooters® brand, Hooters of America, and a franchisee of international Hooters restaurants, will send Irma Guerrero along with a guest to The Hard Rock Hotel in Las Vegas with VIP passes to see the 17th Annual Hooters International Swimsuit Pageant on June 25-29. Ms. Guerrero was the winner, determined by a randomized drawing of more than 6,500 entrants, of a contest sponsored by Chanticleer.

Mike Pruitt, CEO and President, commented, “We congratulate Irma on winning this incredible prize to head to Las Vegas to see the Hooters International Swimsuit Pageant. This annual event has really gained traction over the past 16 years of its existence, and we are excited to continue its success in recognizing Hooters’ hardworking and outstanding competitors.”

The prize includes airfare and hotel reservations and VIP passes for two, to see Hooters crown a new Miss International at the 17th Annual Hooters International Swimsuit Pageant. The pageant will feature the Top 60 Hooters Girls from around the world competing for more than $150,000 in cash and prizes.

About Chanticleer Holdings, Inc. 
Chanticleer Holdings (HOTR) is a franchisee of international Hooters® restaurants and is focused on expanding the Hooters® casual dining restaurant brand in international emerging markets. Chanticleer currently owns in whole or part of the exclusive franchise rights to develop and operate Hooters restaurants in South Africa, Hungary and parts of Brazil, and has joint ventured with the current Hooters franchisee in Australia, while evaluating several additional international opportunities. The Company currently owns and operates in whole or part of six Hooters restaurants in its international franchise territories: Durban, Johannesburg, Cape Town and Emperor’s Palace in South Africa; Campbelltown in Australia; and Budapest in Hungary. Chanticleer maintains a minority ownership stake in Hooters of America and its CEO, Mike Pruitt, is also a member of Hooters’ Board of Directors. Hooters of America is an operator and the franchisor of over 430 Hooters® restaurants in 28 countries.

For further information, please visit www.chanticleerholdings.com
Facebook: www.Facebook.com/ChanticleerHOTR
Twitter: www.Twitter.com/ChanticleerHOTR

For further information on Hooters of America, visit www.Hooters.com
Facebook: www.Facebook.com/Hooters
Twitter: http://Twitter.com/Hooters

Forward-Looking Statements:
Any statements that are not historical facts contained in this release are “forward-looking statements” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “intends,” “estimates,” and other words of similar meaning. Such forward-looking statements are based on current expectations, involve known and unknown risks, a reliance on third parties for information, transactions or orders that may be cancelled, and other factors that may cause our actual results, performance or achievements, or developments in our industry, to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from anticipated results include risks and uncertainties related to the fluctuation of global economic conditions, the performance of management and our employees, our ability to obtain financing or required licenses, competition, general economic conditions and other factors that are detailed in our periodic reports and on documents we file from time to time with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the companies do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

Contact:
Chanticleer Holdings, Inc.
Mike Pruitt
Chairman/CEO
Phone: 704.366.5122 x 1
mp@chanticleerholdings.com

Dian Griesel Inc.
Investor Relations:
Cheryl Schneider
cschneider@dgicomm.com

Public Relations:
Enrique Briz
ebriz@dgicomm.com  
Phone: 212-825-3210

Digiplex (DCIN) to Bring the IMAX Experience® to Arizona’s Surprise Pointe 14

Digital Cinema Destinations Corp. (NASDAQ CM:DCIN) (Digiplex), a rapidly growing exhibitor on the forefront of transforming traditional cinemas into the next generation of digital entertainment centers announces that patrons visiting the Digiplex Surprise Pointe 14 can soon enjoy The IMAX Experience^® when the IMAX^® theatre opens on June 14^th in a specially reconfigured auditorium.

“We’re delighted to partner with such a forward-thinking exhibitor as Digiplex,” said Robert D. Lister, IMAX Chief Legal and Business Development Officer. “Digiplex shares our commitment to quality and innovation and together we look forward to bringing audiences across Arizona Hollywood’s biggest blockbusters in the most immersive format in the world.”

“Digiplex entered the greater Phoenix market last December and we have already introduced a broader range of entertainment choices than any other theater in the area. The opening of this IMAX screen adds another exciting option for our patrons in the western valley,” said Digiplex Chairman and CEO Bud Mayo. “Our relationship with IMAX in Surprise marks the first time we’ve worked together and both companies are enthusiastic about evaluating additional locations throughout the Digiplex circuit as we continue to grow.”

Patrons at Digiplex Destinations Surprise Pointe 14 will take in the world’s most immersive cinematic experience when Man of Steel: An IMAX 3D Experience opens on June 14^th, 2013. The movie has been digitally re-mastered into the image and sound quality of The IMAX Experience^® with proprietary IMAX DMR^® (Digital Re-mastering) technology.

Other upcoming movies to be released in the IMAX format include:

• Pacific Rim: An IMAX 3D Experience (Warner Brothers, July 12, 2013)

The IMAX Experience^® along with Digiplex Destination’s guest service and innovative products and amenities will make Surprise Point 14 a premier destination for entertainment.

About The IMAX Experience^®

In IMAX, you’re experiencing a different movie altogether: everything from the movie itself to the theatre’s technology and design was developed and customized to make you believe you’re part of the action.

IMAX works directly with filmmakers to enhance the movie using its Digital Re-Mastering® process, which delivers superior picture and sound quality. Played through IMAX’s state-of-the art projection system, the resulting images are so lifelike and crystal-clear you’ll forget you’re in a theatre.

IMAX grabs your senses. You don’t just hear the powerful sound system; you feel it all around you. Visually, there is no frame. IMAX’s custom theatre design creates a picture that is higher, wider and closer – filling your peripheral view.

It’s not one thing that makes The IMAX Experience but a combination of all these elements. That’s the difference between seeing a movie and being part of one.

IMAX Is Believing.

About Digital Cinema Destinations Corp. (www.digiplexdest.com)

Digital Cinema Destinations Corp. (NasdaqCM: DCIN) is Digiplex Destinations, dedicated to transforming its movie theaters into interactive entertainment centers. The Company provides consumers with uniquely satisfying experiences, combining state-of-the-art digital technology with engaging, dynamic content that far transcends traditional cinematic fare. The Company’s customers enjoy live opera, ballet, Broadway shows, sports events, concerts and, on an ongoing basis, the very best major motion pictures. Digiplex operates 18 cinemas and 178 digital screens in Arizona, CA, CT, Ohio, PA, and NJ. You can connect with Digiplex via Facebook, Twitter, YouTube and Blogger. Digiplex is also a partner in DigiNext, a unique, specialty content joint venture (with Nehst) featuring curated content from festivals around the world. DigiNext releases typically include innovative live Q&A sessions between the audience and cast members.

(CTCT) SinglePlatform and GrubHub Announce Partnership Agreement

SinglePlatform, a division of Constant Contact®, Inc. (NASDAQ: CTCT), today announced a partnership with GrubHub, a leading online and mobile food ordering service, to become a menu provider for GrubHub’s AllMenus.com and integrate GrubHub’s online ordering platform into SinglePlatform menus.

By making it easier for consumers to locate local restaurant menus and order the food they want, SinglePlatform and GrubHub are helping to drive business to restaurants across the country. In fact, 80 percent of consumers think it is important to see a menu before making a dining decision, according to a recent survey conducted by Chadwick Martin Bailey and SinglePlatform.

“With the nature of today’s on-demand culture, consumers want restaurant information and ordering capabilities at their fingertips,” said Steve Sanger, vice president of business development at GrubHub. “Our goal is to make sure that hungry diners can order takeout whenever, wherever, and SinglePlatform’s customer-verified content gives us the confidence that diners are seeing the latest menu offerings and specials.”

“Purchasing decisions across the board are influenced by what consumers read online or on mobile devices,” said Wiley Cerilli, vice president and general manager of SinglePlatform from Constant Contact. “For restaurants specifically, that’s even more apparent. Our research shows that 75 percent of consumers choose a restaurant based on search results. This partnership with GrubHub makes sure that our customers are part of those search results – and even better, it also enables actual orders, putting real dollars in our customers’ pockets.”

SinglePlatform gives small businesses a single place to update their critical business information and delivers that information across its publishing partner network, including the top three business directory sites, the top three ratings and reviews sites, and dozens of other sites and apps, as well as the business’s social media profiles, website and mobile site. It makes a business listing more than an address and phone number by adding the rich content that consumers want when they are searching for information – such as digital menus, products, pricing, and services. SinglePlatform’s publishing partner network reaches more than 200 million consumers per month.

For more information SinglePlatform and GrubHub, please visit www.singleplatform.com or www.grubhub.com.

About GrubHub

GrubHub is a leading online and mobile food ordering service that shows diners local restaurants available for delivery or pick up. Available in more than 500 cities across the nation, GrubHub features more than 20,000 online ordering restaurants and, as the parent company of Allmenus, lists approximately 250,000 restaurant menus. Diners who order through GrubHub’s free website or mobile apps can pay with cash, credit or PayPal™, and every order is supported by GrubHub’s 24/7 customer service. Founded in 2004, GrubHub is a privately held company and is headquartered in Chicago.

About Constant Contact®, Inc.

Constant Contact wrote the book on Engagement Marketing™ – the new marketing success formula that helps small organizations create and grow customer relationships in today’s socially connected world. More than half a million small businesses, nonprofits and associations worldwide use the company’s online marketing tools to generate new customers, repeat business, and referrals through email marketing, social media marketing, event marketing, local deals, digital storefronts, and online surveys. Only Constant Contact offers the proven combination of affordable tools and free KnowHow®, including local seminars, personal coaching and award-winning product support. The company further supports small organizations through its extensive network of consultants/resellers, technology providers, franchises and national associations.

Constant Contact and the Constant Contact Logo are registered trademarks of Constant Contact, Inc. All Constant Contact product names and other brand names mentioned herein are trademarks or registered trademarks of Constant Contact, Inc. All other company and product names may be trademarks or service marks of their respective owners.

Points (PCOM) Launches New Services for Southwest Airlines Rapid Rewards

Rapid Rewards Members Earn 25% Bonus on All Points Purchased Until July 16

TORONTO, June 4, 2013 (GLOBE NEWSWIRE) — Points (TSX:PTS) (Nasdaq:PCOM), global leader in loyalty currency management, has partnered with Southwest Airlines to bring more services to members of the airline’s loyalty program, Rapid Rewards. To celebrate this new partnership, Southwest Airlines is offering members a 25 percent bonus on all Rapid Rewards points purchased until July 16, 2013. This is the first time the airline has offered a bonus on points purchases.

“We are thrilled to enhance the Rapid Rewards program for our members,” says Ryan Green, Senior Director Loyalty Marketing & Partnerships at Southwest Airlines. “We are committed to delivering the best customer service. Launching our first-ever bonus offer with the new program functionality gives our loyalty members more of what they want: Rapid Rewards Points which have no blackout dates and provide unlimited reward seats,” says Green.

In addition to Buying points, Rapid Rewards members now have the option to Gift and Transfer points to friends and family as part of the new Points-powered services. Rapid Rewards members also gain the flexibility to buy additional points while booking a flight – online or via the customer service center – for redemption at any time.

Points brings more than 13 years of experience and loyalty industry best practices to Southwest Airlines’ Rapid Rewards program. “Southwest Airlines is renowned for its outstanding customer service and growing the Rapid Rewards program is a big part of that,” says Rob MacLean, Chief Executive Officer of Points. “This launch is the first stage in our partnership towards adding more flexibility and opportunity for Rapid Rewards members, and we look forward to helping the team at Southwest continue to enhance this great program,” says MacLean.

For more information on the Rapid Rewards bonus offer visit www.Southwest.com/BuyPoints. For more information on Points visit www.Points.com.

About Points

Points, publicly traded as Points International Ltd. (TSX:PTS) (Nasdaq:PCOM), is the global leader in loyalty currency management. Via a state-of-the-art loyalty commerce platform, Points provides loyalty eCommerce and technology solutions to the world’s top brands to enhance their consumer offerings and streamline their back-end operations.

Points’ solutions enhance the management and monetization of loyalty currencies ranging from frequent flyer miles and hotel points to retailer and credit card rewards, for more than 45 partners worldwide. In addition to these services, Points’ unique SaaS products allow eCommerce merchants to add loyalty solutions directly to their online stores, rewarding customers for purchases at the point-of-sale.

For more information on Points, please visit www.Points.com, follow us @PointsBiz on Twitter or read the Points Loyalty News blog.

ABOUT SOUTHWEST AIRLINES CO.

In its 42^nd year of service, Dallas-based Southwest Airlines (NYSE:LUV) continues to differentiate itself from other carriers with exemplary Customer Service delivered by nearly 46,000 Employees to more than 100 million Customers annually. Southwest is the nation’s largest carrier in terms of originating domestic passengers boarded, and including wholly-owned subsidiary, AirTran Airways, operates the largest fleet of Boeing aircraft in the world to serve 97 destinations in 41 states, the District of Columbia, the Commonwealth of Puerto Rico, and six near-international countries. Southwest is one of the most honored airlines in the world, known for its triple bottom line approach that takes into account the carrier’s performance and productivity, the importance of its People and the communities it serves, and its commitment to efficiency and the planet. The 2011 Southwest Airlines One Report™ can be found at southwest.com/citizenship.

Southwest Airlines

From its first flights on June 18, 1971, Southwest Airlines launched an era of unprecedented affordability in air travel quantified by the U.S. Department of Transportation as “The Southwest Effect,” a lowering of fares and increase in passenger traffic wherever the carrier serves. On every flight, Southwest offers Customers the first two pieces of checked luggage (weight and size limitations apply) and all ticket changes without additional fees. Southwest’s all Boeing fleet consistently offers leather seating and the comfort of full-size cabins, many of which are equipped with satellite-based WiFi connectivity and a new, sustainable cabin interior. With 40 consecutive years of profitability, the People of Southwest operate nearly 3,400 flights a day and serve communities around 84 airports in Southwest’s network of domestic destinations. Southwest Airlines’ frequent flights and low fares are available only at southwest.com.

AirTran Airways

AirTran Airways, a wholly-owned subsidiary of Southwest Airlines Co., offers coast-to-coast and near-international service with close to 600 flights a day to 49 destinations. The carrier’s high-quality product includes assigned seating and Business Class. As Southwest continues to integrate AirTran’s People, places, and planes into Southwest Airlines, Customers of both carriers may book flights at airtran.com and exchange earned loyalty points between both AirTran’s A+ Rewards® and Southwest’s Rapid Rewards® for reward travel on either airline.

CONTACT: For more information contact:

         Points Media relations:
         Fiona Pincente
         Corporate Communications Manager, Points
         T. 416.596.6370 x3130; E. fiona.pincente@points.com

         Points Investor relations:
         Laura Bainbridge/Kimberly Esterkin, Addo Communications
         T.310.829.5400;
         E. laurab@addocommunications.com; kimberlye@addocommunications.com

         Southwest Media Relations:
         Katie McDonald
         Southwest Airlines Media Relations
         T. 214.792.4847; E. katie.mcdonald@wnco.com

Fibrocell Science (FCSC) CEO Rings the New York Stock Exchange Closing Bell

Fibrocell Science, Inc. (NYSE MKT: FCSC), an autologous cell therapy company focused on the development of innovative products for aesthetic, medical and scientific applications, announced today that Chief Executive Officer and Chairman David Pernock, will preside over the Closing Bell on Tuesday, June 4, 2013 at 4 p.m. Eastern Time at the New York Stock Exchange.

“We are pleased that the New York Stock Exchange has given Fibrocell the honor of ringing the Closing Bell. This occasion marks the successful listing of our stock on the NYSE MKT,” Pernock said. “We are focused on expanding the applications of our FDA-approved product, LAVIV® (azficel-T), to areas of significant unmet medical needs such as restrictive burn scarring, vocal cord scarring and acne scarring.”

“In addition, we have entered into an exclusive channel collaboration (ECC) with Intrexon Corporation to explore the use of genetically-modified autologous fibroblast cells for Recessive Dystrophic Epidermolysis Bullosa, the most severe form of a debilitating genetic blistering disorder,” Pernock said.

The Closing Bell is televised live on CNBC and also airs online at https://nyse.nyx.com/the-bell/todays-bells-live at 4 p.m. ET. Web viewers may need to refresh their browsers ahead of 4 p.m. to start the live feed.

Photographs from the Closing Bell ceremony and a recording of the event, provided by NYSE, will be available on www.fibrocellscience.com on Wednesday, June 5, 2013.

About Fibrocell Science, Inc.

Fibrocell Science, Inc. (FCSC) is an autologous cell therapy company focused on the development of innovative products for aesthetic, medical and scientific applications. Fibrocell Science is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well as its innovative cellular processing technology and manufacturing excellence. For additional information, please visit www.fibrocellscience.com.

About LAVIV® (azficel-T)

LAVIV is the first and only autologous fibroblast cellular product approved by the FDA to improve the appearance of moderate to severe nasolabial fold (smile line) wrinkles in adults. It has been evaluated in more than 1,000 patients in clinical studies, including two pivotal Phase III trials. The safety and efficacy of LAVIV for areas other than the nasolabial folds have not been established. The efficacy of LAVIV beyond six months has not been established.

Important Safety Information about LAVIV® (azficel-T)

LAVIV (azficel-T) is an autologous cellular product for intradermal injection only. LAVIV is contraindicated for allogeneic use, in patients with allergy to gentamicin, amphotericin, dimethyl sulfoxide (DMSO) or material of bovine origin and in patients with active infection in the facial area. The following reactions have been reported following treatment with LAVIV: hypersensitivity reactions, bleeding and bruising at the treatment site, vasculitis, herpes labialis, basal cell cancer; keloid and hypertrophic scarring may occur following post-auricular skin biopsies or LAVIV injections. Additional warnings and precautions to be considered include the use of LAVIV in patients with genetic disorders or formation of normal collagen matrices and in immunosuppressed patients, or those patients undergoing chemotherapy for malignancies or receive immunomodulatory therapies for autoimmune diseases.

The most common adverse reactions, occurring in ≥1% of patients who receive LAVIV, were injection-site redness, bruising, swelling, pain, hemorrhage, edema, nodules, papules, irritation, dermatitis and pruritus.

For more information about LAVIV, please see the accompanying full Prescribing Information or visit www.mylaviv.com.

Forward-Looking Statements

All statements in this press release that are not based on historical fact are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, without limitation, the Company’s ability to expand the indications of azficel-T into significant medical applications for which there are no currently approved medical options. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of the Company’s control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012, as updated in “Item 1A. Risk Factors” in the Company’s Quarterly Reports on Form 10-Q filed since the annual report. The Company operates in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. The Company disclaims any intention to, and undertakes no obligation to, update or revise any forward-looking statements. Readers are also urged to carefully review and consider the other various disclosures in the Company’s public filings with the SEC.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20130604006814/en/

Rosetta Genomics (ROSG) to Increase the Number of U.S. Sales Territories

Launches new corporate and product branding at ASCO 2013, reports strong attendance at Industry Expert Theater Presentation

PHILADELPHIA and REHOVOT, Israel, June 4, 2013 /PRNewswire/ — Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces plans to expand its U.S. commercial footprint from five sales territories currently to 12 territories beginning in July 2013.   In addition, the Company reports the successful launch of its new corporate and product branding at the recent American Society of Clinical Oncology Annual Meeting (ASCO 2013).

“Our Rosetta Cancer Origin Test™ (formerly miRview^® mets²) has been trending positively for the past three months in terms of samples processed and samples billed. We continue to make progress in executing agreements with Preferred Provider Organizations (PPOs), such as our recently announced credentialing agreement with Prime Health, which now allow for this test to be adjudicated as ‘in network’ for more than 6.5 million patients in the U.S.  Our strong presence at ASCO 2013 significantly enhanced the knowledge of and interest in our microRNA-based cancer testing services.  Consequently, we believe the time is right for a strategic expansion of our sales force in order to achieve greater reach to physicians, and ultimately to ensure that our Cancer Origin Test^™ is available to more patients,” said Kenneth A. Berlin, Rosetta Genomics’ President and Chief Executive Officer.

Rosetta Genomics unveiled its new corporate and product branding at ASCO 2013 through various mediums including an interactive tradeshow booth that featured a high-definition promotional video and various other promotional materials. The new branding includes an updated corporate logo with the tagline, “expanding personalized medicine,” and new names and logos for Rosetta’s Cancer Testing Services (formally the miRview^® family of testing services), all of which were extremely well received by healthcare professionals who visited the booth.

In addition, Rosetta’s Cancer Testing Services were highlighted in an “Industry Expert Theater Presentation” (IETP), during which Mr. Berlin and E. Robert Wassman, MD, FAAP, FACMG, Rosetta Genomics’ Chief Medical Officer, delivered a presentation entitled, “Application of microRNAs in Oncology Diagnostics.” Dr. Wassman delivered a presentation on the Cancer Origin Test^™.  During his presentation, Dr. Wassman discussed real-world case studies of patients with Cancer of Unknown or Uncertain Primary (CUP) impacted by the test results, and reviewed data from extensive validation studies that demonstrated a high level of concordance with the predictions made by leading CUP centers.

“We are delighted with the positive reception to our IETP, and with the caliber of questions asked. We believe that through educational programs like this and our other physician outreach efforts, physicians are beginning to acknowledge the clinical value of microRNA profiling in CUP patients, and recognize that it is not a matter of whether to use such diagnostics but when to use them.  In many cases a diagnosis of Cancer of Unknown Primary is no longer acceptable now that we have more precise diagnostic assays to identify the tumor of origin and, therefore, are able to make better clinical treatment decisions,” said Dr. Wassman.

Mr. Berlin added, “We received very favorable feedback on our new corporate and product branding.  We believe our modern new look and fresh promotional materials, as well as our highly successful IETP, made a significant contribution to the steady flow of visitors to our booth, and the subsequent sales leads recorded. The positive responses confirmed that our new corporate branding conveys who we are and what we do extremely well. In addition, visitors to our booth gave highly positive feedback relating to the new names and logos for our Cancer Testing Services, citing that they like the clear connection between our corporate brand and what the tests actually do.”

About Rosetta Cancer Testing Services (formerly the miRview^® product line)
Rosetta Cancer Tests are a series of microRNA-based diagnostic testing services offered by Rosetta Genomics. The Rosetta Cancer Origin Test^™ can accurately identify the primary tumor type in primary and metastatic cancer including cancer of unknown or uncertain primary (CUP). Rosetta Mesothelioma Test^™ diagnoses mesothelioma, a cancer connected to asbestos exposure.  The Rosetta Lung Cancer Test^™ accurately identifies the four main subtypes of lung cancer using small amounts of tumor cells. The Rosetta Kidney Cancer Test^™ accurately classifies the four most common kidney tumors: clear cell renal cell carcinoma (RCC), papillary RCC, chromophobe RCC and oncocytoma.  Rosetta’s assays are designed to provide objective diagnostic data; it is the treating physician’s responsibility to diagnose and administer the appropriate treatment.  In the U.S. alone, Rosetta Genomics estimates that 200,000 patients a year may benefit from the Rosetta Cancer Origin Test^™, 60,000 from the Rosetta Mesothelioma Test^™, 65,000 from the Rosetta Kidney Cancer Test^™ and 226,000 patients from the Rosetta Lung Cancer Test^™. The Company’s assays are offered directly by Rosetta Genomics in the U.S., and through distributors around the world. For more information, please visit www.rosettagenomics.com. Parties interested in ordering the test can contact Rosetta Genomics at (215) 382-9000 ext. 1309.

About Rosetta Genomics
Rosetta develops and commercializes a full range of microRNA-based molecular diagnostics.  Founded in 2000, Rosetta’s integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools. Rosetta’s cancer testing services are commercially available through its Philadelphia-based CAP-accredited, CLIA-certified lab.  Frost & Sullivan recognized Rosetta Genomics with the 2012 North American Next Generation Diagnostics Entrepreneurial Company of the Year Award.

Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta’s future expectations, plans and prospects, including without limitation, the expectation that expansion of Rosetta’s sales force will achieve greater reach to physicians, and ensure that the Cancer Origin Test^™ will be available to more patients,  constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the “Risk Factors” section of Rosetta’s Annual Report on Form 20-F for the year ended December 31, 2012 as filed with the SEC. In addition, any forward-looking statements represent Rosetta’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

Company Contact:
Rosetta Genomics
Ken Berlin, President & CEO
(215) 382-9000, ext. 1326
investors@rosettagenomics.com

Investor Contacts:
LHA
Anne Marie Fields
(212) 838-3777
afields@lhai.com
or
Bruce Voss
(310) 691-7100
bvoss@lhai.com

(QIWI) Announces First Quarter 2013 Results

Adjusted Net Revenue Increased 50% to RUB 1,284 Million

Adjusted Net Profit Increased 216% to RUB 455 Million

Successfully Completed Initial Public Offering in May

MOSCOW, June 4, 2013 (GLOBE NEWSWIRE) — QIWI plc, (Nasdaq:QIWI) (“QIWI” or the “Company”) today announced results for the first quarter ended March 31, 2013.

First Quarter 2013 Operating and Financial Highlights

• Adjusted Net Revenues increased by 50% to RUB 1,284 million ($41.3 million) from RUB 857 million in the prior year period.
• Adjusted EBITDA increased by 105% to RUB 611 million ($19.6 million) from RUB 298 million in the prior year period. Adjusted EBITDA margin improved to 47.6% from 34.7% in the prior year period.
• Adjusted Net Profit increased by 216% to RUB 455 million ($14.7 million) from RUB 144 million in the prior year period.
• The number of active Visa QIWI wallet accounts as of March 31, 2013 was approximately 13.0 million (on a rolling 12 months basis), representing an increase of 49% over 8.7 million as of March 31, 2012.
• Visa QIWI Wallet payment volume increased by 107% to RUB 53.7 billion ($1.73 billion), and average net revenue yield increased by 3 basis points (bps) to 0.94% over the prior year period.
• QIWI Distribution payment volume increased by 14% to RUB 117.3 billion ($3.77 billion), and average net revenue yield increased by 8 bps to 0.65% over the prior year period.

“QIWI is pleased to report a strong start to 2013. Our first quarter results are a testament to the value of our integrated proprietary network, our comprehensive suite of differentiated payment services, and our leading position in the fast-growing markets we serve,” said Sergey Solonin, QIWI’s chief executive officer. “We remain excited by the wide range of growth opportunities available to us including continuing to capitalize on strong secular trends in the Russian and CIS markets and the rapid adoption of our Visa Qiwi Wallet. We will continue to build on our accomplishments with a focus on creating long-term value.”

First Quarter 2013 Results

Revenues: Adjusted net revenue was RUB 1,284 million ($41.3 million), representing an increase of 50% as compared to RUB 857 million in the prior year.

QIWI Distribution segment net revenue for the quarter ended March 31, 2013 was RUB 758 million ($24.4 million), representing an increase of 29% as compared to RUB 590 million for the same period in the prior year. QIWI Distribution segment net revenue growth was primarily driven by an increase in payment volume in active kiosks and terminals and an increase in net revenue yield primarily driven by growth of our value added services.

Visa QIWI Wallet segment net revenue for the quarter ended March 31, 2013 was RUB 505 million ($16.2 million), representing an increase of 113% as compared to RUB 236 million for the same period in the prior year. Visa QIWI Wallet segment net revenue growth was primarily driven by an increase in payment volume.

Adjusted EBITDA: For the quarter ended March 31, 2013 Adjusted EBITDA was RUB 611 million ($19.6 million), representing an increase of 105% as compared to RUB 298 million for the same period in the prior year. The increase in Adjusted EBITDA was primarily driven by the aforementioned growth in revenue and significant operating leverage in the business. Adjusted EBITDA margin (Adjusted EBITDA as a percentage of total Adjusted Net Revenues) improved significantly to 47.6% from 34.7% in the prior year.

Adjusted Net Profit: For the quarter ended March 31, 2013 Adjusted net profit was RUB 455 million ($14.7 million) or (RUB 8.75 per diluted share), representing an increase of 216% as compared to RUB 144 million or (RUB 2.77 per diluted share) for the same period in the prior year. The increase in Adjusted net profit was primarily driven by the same factors impacting Adjusted EBITDA.

Other Operating Data: For the quarter ended March 31, 2013 QIWI Distribution payment volume was RUB 117.3 billion ($3.77 billion), representing an increase of 14% as compared to RUB 103.2 billion for the same period in the prior year. The increase in payment volume in QIWI Distribution was primarily driven by an increase in Visa QIWI Wallet users reloading their wallets through the QIWI Distribution network. Average QIWI Distribution net revenue yield for the same period was 0.65%, representing an increase of 8 bps as compared to 0.57% in the prior year period.

For the quarter ended March 31, 2013 Visa QIWI Wallet payment volume was RUB 53.7 billion ($1.73 billion), representing an increase of 107% as compared to RUB 26.0 billion in the prior year. The increase in payment volume in Visa QIWI Wallet resulted from several major factors, including the continued increase in the number of active users and the increase in the average volume per Visa QIWI Wallet account. The number of active Visa QIWI Wallet accounts in the first quarter 2013 was approximately 13.0 million, representing an increase of 49% compared to approximately 8.7 million in the first quarter 2012. Average volume per Visa QIWI Wallet in the first quarter of 2013 was RUB 4,134 ($133), representing an increase of 38% compared to RUB 2,987 ($96) in the prior year. Average Visa QIWI Wallet net revenue yield for the same period was 0.94%, representing an increase of 3 bps compared to 0.91% in the first quarter 2012 or an increase of 16 bps as compared with 0.78% in the fourth quarter 2012.

Recent Developments

Initial Public Offering: On May 8, 2013 QIWI successfully completed its previously announced initial public offering of 12,500,000 Class B Shares in the form of American Depositary Shares (ADS) at a price of $17.00 per ADS.

Special dividend: On May 31, 2013 following the determination of first quarter 2013 financial results the Board of Directors of QIWI approved a special dividend of $15,080,000.00 or $0.29 per share. The dividend record date is June 17, 2013, and the Company intends to pay the dividend on June 18, 2013. The holders of ADSs will receive the dividend shortly thereafter.

2013 Guidance

• Adjusted Net Revenue for 2013 is expected to increase from 23% to 26% over 2012.
• Adjusted Net Profit for 2013 is expected to increase 27% to 33% over 2012.

This guidance reflects QIWI’s current and preliminary view, which is subject to change.

Earnings Conference Call and Audio Webcast

The Company will host a conference call to discuss first quarter 2013 financial results today at 8:30 a.m. EDT. Hosting the call will be Sergey Solonin, chief executive officer, and Alexander Karavaev, chief operating officer. The conference call can be accessed live over the phone by dialing +1 (877) 407-3982 or for international callers by dialing +1 (201) 493-6780. A replay will be available today at 11:30 a.m. ET and can be accessed by dialing +1 (877) 870-5176 or +1 (858) 384-5517 for international callers; the pin number is 414881. The replay will be available until Tuesday, June 11, 2013. The call will be webcast live from the Company’s website at https://www.qiwi.ru under the Corporate Investor Relations section or directly at http://investor.qiwi.com/.

About QIWI plc.

QIWI is a leading provider of next generation payment services in Russia and the CIS. It has an integrated proprietary network that enables payment services across physical, online and mobile channels. It has deployed approximately 13 million virtual wallets, over 165,000 kiosks and terminals, and enabled over 47,000 merchants to accept over RUB 41 billion cash and electronic payments monthly from over 60 million consumers using its network at least once a month. QIWI’s consumers can use cash, stored value and other electronic payment methods to order and pay for goods and services across physical or online environments interchangeably.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of, and subject to the protection of, the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding expected revenue and net profits, dividend payments, the growth of Visa QIWI Wallet, payment volume growth, and growth in the Company’s distribution network. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance or achievements of QIWI plc. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Various factors that could cause actual future results and other future events to differ materially from those estimated by management include, but are not limited to, competition, a decline in average net revenue yield, fees levied on QIWI’s consumers, regulation, QIWI’s ability to grow Visa QIWI Wallet, QIWI’s ability to expand geographically and other risks identified under the Caption “Risk Factors” in QIWI’s Registration Statement on Form F-1 and in reports QIWI files with the U.S. Securities and Exchange Commission. QIWI undertakes no obligation to release publicly any revisions to any forward-looking statements, to report events or to report the occurrence of unanticipated events unless we are required to do so by law.

Non-IFRS Financial Measures

This release presents Adjusted Net Revenue, Adjusted EBITDA, Adjusted Net Profit, and Adjusted Net Profit per share, which are non-IFRS financial measures. You should not consider these non-IFRS financial measures as substitutes for or superior to revenue, in the case of Adjusted Net Revenue, or net profit, in the case of Adjusted EBITDA and Adjusted Net Profit, each prepared in accordance with IFRS. Furthermore, because these non-IFRS financial measures are not determined in accordance with IFRS, they are susceptible to varying calculations and may not be comparable to other similarly titled measures presented by other companies. We encourage investors and others to review our financial information in its entirety and not rely on a single financial measure. For more information regarding Adjusted Net Revenue, Adjusted EBITDA, Adjusted Net Profit, and Adjusted Net Profit per share, including a quantitative reconciliation of Adjusted Net Revenue, Adjusted EBITDA and Adjusted Net Profit to the most directly comparable IFRS financial performance measure, which is revenue in the case of Adjusted Net Revenue, and net profit in the case of Adjusted EBITDA and Adjusted Net Profit, see Reconciliation of IFRS to Non-IFRS Operating Results in this earnings release.

In this release, Russian ruble (RUB) amounts have been translated into U.S. dollars at a rate of RUB 31.0834 to $1.00, the official exchange rate quoted as of March 31, 2013 by the Central Bank of the Russian Federation.

CONTACT: Investor Contact
         +7.499.709.0192
         ir@qiwi.com

(MHGC) Slate Of Director Nominees To Explore Full Range Of Strategic Alternatives

Announcement Follows Feedback from Company Stockholders and Recent Receipt of Expressions of Interest to Acquire the Company from Five Potential Strategic Buyers

NEW YORK, June 4, 2013 /PRNewswire/ — Morgans Hotel Group Co. (NASDAQ: MHGC) (“MHG” or the “Company”) today announced that its slate of director nominees intends to initiate a process to explore strategic alternatives, including a sale of the Company, upon re-election at the Company’s Annual Meeting of Stockholders on June 14, 2013. The announcement was made in response to feedback from the Company’s stockholders and the recent receipt of unsolicited expressions of interest to acquire the Company from five potential strategic buyers.

There is no assurance that this process of exploring strategic alternatives, if our Board’s director nominees are elected, will result in MHG changing its business plan, pursuing a particular strategic alternative or transaction or completing any such strategic alternative or transaction.

ABOUT MORGANS HOTEL GROUP

Morgans Hotel Group Co. (NASDAQ: MHGC) is widely credited as the creator of the first “boutique” hotel and a continuing leader of the hotel industry’s boutique sector. Morgans Hotel Group operates Delano in South Beach and Marrakech, Mondrian in Los Angeles, South Beach and New York, Hudson in New York, Morgans and Royalton in New York, Shore Club in South Beach, Clift in San Francisco, Ames in Boston and Sanderson and St Martins Lane in London. Morgans Hotel Group has ownership interests or owns several of these hotels. Morgans Hotel Group has other property transactions in various stages of completion, including Delano properties in Las Vegas, Nevada; Cesme, Turkey and Moscow, Russia; Mondrian properties in London, England; Istanbul, Turkey; Doha, Qatar and Baha Mar in Nassau, The Bahamas; and a Hudson in London, England. Morgans Hotel Group also owns a 90% controlling interest in The Light Group, a leading lifestyle food and beverage company. For more information please visit www.morganshotelgroup.com.

FORWARD-LOOKING AND CAUTIONARY STATEMENTS

This press release may contain certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.  Such forward-looking statements relate to, among other things, the intention of our Board nominees to explore strategic alternatives if elected, and any potential strategic transaction that may result from any such process.  Forward-looking statements are generally identifiable by use of forward-looking terminology such as “may,” “will,” “should,” “potential,” “intend,” “expect,” “endeavor,” “seek,” “anticipate,” “estimate,” “overestimate,” “underestimate,” “believe,” “could,” “project,” “predict,” “continue” or other similar words or expressions. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties, assumptions and changes in circumstances that may cause actual events or our actual results to differ materially from those expressed in any forward-looking statement.  Important risks and factors that could cause actual events or our actual results to differ materially from those expressed in any forward-looking statements include, but are not limited to whether any potential counterparty would be willing to enter into a sales transaction on acceptable terms or at all, as well as economic, business, competitive market and regulatory conditions such as: a sustained downturn in economic and market conditions, both in the U.S. and internationally, particularly as it impacts demand for travel, hotels, dining and entertainment; our levels of debt, our ability to refinance our current outstanding debt, repay outstanding debt or make payments on guaranties as they may become due, our ability to access the capital markets and the ability of our joint ventures to do the foregoing; our history of losses; our ability to compete in the “boutique” or “lifestyle” hotel segments of the hospitality industry and changes in the competitive environment in our industry and the markets where we invest; our ability to protect the value of our name, image and brands and our intellectual property; risks related to natural disasters, terrorist attacks, the threat of terrorist attacks and similar disasters; and other risk factors discussed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2012, which was filed with the Securities and Exchange Commission (the “SEC”) on March 6, 2013, as amended by the Form 10-K/A filed on April 30, 2013, and other documents filed by the Company with the SEC from time to time. In particular, on May 14, 2013, the Delaware Court of Chancery entered an order, among other things, prohibiting the Company from taking any steps to consummate the previously announced proposed deleveraging transaction until the earlier of a trial on the merits of the pending action or a decision by our Board with respect to the proposed deleveraging transaction made at a properly noticed meeting after due deliberation and after receiving a favorable recommendation from the special transaction committee. Given the Delaware Court’s ruling, there is substantial uncertainty as to the status of the agreements related to the proposed deleveraging transaction. We cannot provide any assurance as to whether, or when and on what terms, the proposed deleveraging transaction will be considered or consummated and what impact if any that proposed transaction would have on any process to explore strategic alternatives. See the Company’s definitive 2013 proxy statement, filed with the SEC on May 23, 2013, for more detail. All forward-looking statements in this press release are made as of the date hereof, based upon information known as of the date hereof, and the Company assumes no obligations to update or revise any of its forward-looking statements even if experience or future changes show that indicated results or events will not be realized.

IMPORTANT ADDITIONAL INFORMATION

On May 23, 2013, the Company filed a definitive proxy statement and WHITE proxy card with the SEC in connection with the solicitation of proxies for its 2013 Annual Meeting of Stockholders. Stockholders are strongly advised to read the Company’s 2013 proxy statement because it contains important information. Stockholders may obtain a free copy of the 2013 proxy statement and other documents that the Company files with the SEC from the SEC’s website at www.sec.gov or the Company’s website at www.morganshotelgroup.com.

Capstone (CPST) C800/CC125 Order Goes Out to New Anaerobic Digester System

CHATSWORTH, Calif., June 3, 2013 (GLOBE NEWSWIRE) — Capstone Turbine Corporation (www.capstoneturbine.com) (Nasdaq:CPST), the world’s leading clean technology manufacturer of microturbine energy systems, today announced it received an order from CleanWorld Partners, an internationally recognized technology innovator in anaerobic digestion technology and by-product utilization. The order includes a Capstone C800 Microturbine and Capstone Clean Cycle 125kW (CC125) waste heat-to-electricity generator.

Regatta Solutions, Inc., Capstone’s distributor for California, Oregon, Washington and Hawaii, secured the order.

The grid-connected system will be installed this summer in a combined heat and power (CHP) application at an innovative organic-waste-to-renewable energy facility at a university nationally acclaimed as a sustainability leader.

The ultra-low emission C800 and CC125 will provide a portion of the site’s electric load. All waste heat produced from operation of the C800 will heat an on-site digester and, along with waste heat from the digester, run the CC125 — all without any need for additional fuel.

Biogas produced by the digester, which sits atop a landfill, will fuel the clean-and-green C800.

“CleanWorld has achieved widespread success in anaerobic digester solutions, significantly reducing greenhouse-gas emissions, with scalable and affordable solutions,” said Michelle Wong, Chief Executive Officer of CleanWorld Partners. “Capstone microturbines align with our mission to implement effective renewable solutions that mitigate emissions and capture loss of energy through a waste and heat conversion process.”

“Using this dynamic combination of the C800 and CC125 in a renewable energy anaerobic digester is the perfect example of how Capstone microturbines provide cleaner, more reliable, and cost-effective power solutions,” said Jim Crouse, Capstone’s Executive Vice President of Sales and Marketing. “The CC125’s Organic Rankine Cycle (ORC) captures normally wasted heat from a variety of sources and turns the heat into clean-and-green electricity, which significantly raises a power-system’s net efficiency.”

The Capstone microturbines’ reliability was a key factor for the purchase. “CleanWorld plans to resell electricity generated onsite under a Power Purchase Agreement to the university. It’s critical that the system run without interruption,” Crouse said.

“CleanWorld Partners is internationally recognized for its forward-thinking approach in the renewable-energy market,” said Darren Jamison, Capstone President and Chief Executive Officer. “The company’s innovation, paired with Capstone’s clean-and-green technology, provides an unrivaled foundation that enables companies to meet their zero-waste initiatives.”

About Capstone Turbine Corporation

Capstone Turbine Corporation (www.capstoneturbine.com) (Nasdaq:CPST) is the world’s leading producer of low-emission microturbine systems and was the first to market commercially viable microturbine energy products. Capstone Turbine has shipped over 6,500 Capstone Microturbine systems to customers worldwide. These award-winning systems have logged millions of documented runtime operating hours. Capstone Turbine is a member of the U.S. Environmental Protection Agency’s Combined Heat and Power Partnership, which is committed to improving the efficiency of the nation’s energy infrastructure and reducing emissions of pollutants and greenhouse gases. A UL-Certified ISO 9001:2008 and ISO 14001:2004 certified company, Capstone is headquartered in the Los Angeles area with sales and/or service centers in the New York Metro Area, Mexico City, Nottingham, Shanghai and Singapore.

The Capstone Turbine Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6212

This press release contains “forward-looking statements,” as that term is used in the federal securities laws, about the reliability of our products and their use in the renewable energy market. Forward-looking statements may be identified by words such as “expects,” “objective,” “intend,” “targeted,” “plan” and similar phrases. These forward-looking statements are subject to numerous assumptions, risks and uncertainties described in Capstone’s filings with the Securities and Exchange Commission that may cause Capstone’s actual results to be materially different from any future results expressed or implied in such statements. Capstone cautions readers not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Capstone undertakes no obligation, and specifically disclaims any obligation, to release any revisions to any forward-looking statements to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

“Capstone” and “Capstone MicroTurbine” are registered trademarks of Capstone Turbine Corporation. All other trademarks mentioned are the property of their respective owners.

CONTACT: Capstone Turbine Corporation
         Investor and investment media inquiries:
         818-407-3628
         ir@capstoneturbine.com

Agilysys (AGYS) to Sell Retail Solutions Group to Clearlake for $34.55M Cash

Agilysys, Inc. (Nasdaq: AGYS), a leading developer and marketer of proprietary enterprise software, services and solutions to the hospitality and retail industries, today announced that it has entered into a definitive agreement to sell its Retail Solutions Group (“RSG”) to an affiliate of Clearlake Capital Group, L.P. (“Clearlake”) for total consideration of $34.55 million in cash, subject to customary closing conditions.

Following completion of the proposed transaction, expected to occur later this summer, Agilysys’ business will be focused exclusively on providing software enabled solutions to the hospitality industry. The Company estimates that, as of the closing, it will have approximately $110 million in cash and cash equivalents, representing approximately $4.90 per common share outstanding, and no debt. The Company believes its strong balance sheet and positive adjusted operating income positions it to execute on growth initiatives in the hospitality industry. Through continued investments in new product development as well as potential acquisitions, the Company expects to grow its business, add to its solutions portfolio and deliver above market returns to shareholders.

James Dennedy, President and Chief Executive Officer of Agilysys, commented, “The sale of the RSG business is consistent with our corporate strategy of pursuing the highest return on capital opportunities available to the Company for the benefit of our employees, customers and shareholders. Looking forward, we expect Agilysys to generate positive adjusted operating income with above market growth from its hospitality focused business.”

Mr. Dennedy added, “The RSG business contains a talented team of people and leadership offering compelling solutions to the retail industry. The transaction provides the business and the team access to greater capital to pursue the growth initiatives available in the retail market. Clearlake is a great partner to help grow the business, further develop the team, and serve the RSG customers.”

“We are excited to invest in RSG, a clear market leader with strong customer relationships, as we provide new capital to accelerate growth,” said Behdad Eghbali, a founding partner at Clearlake. “We view RSG as a strong platform with talented leadership that is well-positioned to benefit from significant market trends, including retailers’ continuing investment in information technology to enhance the customer experience. We look forward to supporting management as they build on RSG’s track record of delivering exceptional value to customers.”

Additional Financial and Reporting Details

Agilysys will report financial results for the three and twelve-month periods ended March 31, 2013, on June 12, 2013. On January 31, 2013, Agilysys provided fiscal 2013 financial guidance, inclusive of Retail contributions, for revenue of $230-$232 million, adjusted operating income of $6.0-$6.5 million and adjusted earnings per share of $0.24-$0.26.

Agilysys expects to record a one-time restructuring charge of less than $1.0 million related to the sale of RSG in its fiscal 2014 and does not expect to pay income taxes on the proceeds of the sale.

The estimated $110 million of cash and cash equivalents at closing is based on the forecasted value of cash on hand as of the closing, plus the net proceeds from the RSG sale transaction, less restructuring related cash expenses.

Forward-Looking Language

This press release and other publicly available documents, including the documents incorporated herein and therein by reference, contain, and our officers and representatives may from time to time make, “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods, including the last two sentences of the second paragraph and the second sentence of the third paragraph of this press release. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. These statements are based on management’s current expectations, intentions or beliefs and are subject to a number of factors, assumptions and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Factors that could cause or contribute to such differences or that might otherwise impact the business include the risk factors set forth in Item 1A of the company’s Annual Report for the fiscal year ended March 31, 2012. Copies are available from the SEC or the Agilysys website. We undertake no obligation to update any such factor or to publicly announce the results of any revisions to any forward-looking statements contained herein whether as a result of new information, future events or otherwise.

Guidance

Guidance figures are based on the Company’s current estimates and are subject to change by factors outside the Company’s control. While this guidance is provided to give investors insight into expectations for the period, actual results may vary.

About Agilysys

Agilysys is a leading developer and marketer of proprietary enterprise software, services and solutions to the hospitality and retail industries. The company specializes in market-leading point-of-sale, property management, inventory & procurement and mobile & wireless solutions that are designed to streamline operations, improve efficiency and enhance the guest experience. Agilysys serves casinos, resorts, hotels, foodservice venues, stadiums, cruise lines, grocery stores, convenience stores, general & specialty retail businesses and partners. Agilysys operates extensively throughout North America, Europe and Asia, with corporate services located in Alpharetta, GA, EMEA headquarters in Cheshire, UK and APAC offices in both Singapore and Hong Kong. For more information, visit agilysys.com.

About Clearlake Capital Group

Clearlake Capital Group, L.P. is a private investment firm focused on special situations and private equity investments such as corporate divestitures, recapitalizations, buyouts, reorganizations, turnarounds and other equity investments. Clearlake seeks to partner with world-class management teams by providing patient, long-term capital and operational expertise to invest in dynamic businesses. Clearlake currently manages approximately $1.4 billion of equity capital, and Clearlake’s founding principals have led over 50 investments totaling more than $3 billion of capital in sectors including business services, communication, consumer products/retail, defense/public safety, energy/power, healthcare, industrials, media, and technology. For more information, please visit www.clearlakecapital.com.

Pixelworks (PXLW) to Unveil Tablet and Ultrabook Display Processor Technology

Pixelworks, Inc. (NASDAQ: PXLW) today announced that it is bringing its innovative video display processor technology to Tablets and Ultrabooks. At invitation-only meetings at this year’s COMPUTEX TAIPEI, the company will demonstrate its technology for the highest quality video on Windows 8™ Tablets and Ultrabooks based on Intel’s 4^th generation Core™ processors.

With the increase of media consumption across all screens, users are demanding the best picture quality for their movies, photos and video games. Traditionally this type of video display processing has only been available for large screens. Utilizing an innovative new approach, Pixelworks is able to bring the highest display quality to Tablets and Ultrabooks.

“Pixelworks has always been about video quality, and we believe that every screen, especially the highest resolution Tablets and Ultrabooks, are ideal platforms for the very best video processing technology,” said Graham Loveridge, Sr. Vice President of Marketing at Pixelworks.

To obtain an invitation to the Pixelworks suite at COMPUTEX, or for additional information about Pixelworks’ products, including the company’s newest video display processor solutions for Tablets and Ultrabooks, please contact your local Pixelworks office (http://www.pixelworks.com/locations.php).

About Pixelworks, Inc.

Pixelworks creates, develops and markets video display processing technology for digital video applications that demand the very highest quality images. At design centers around the world, Pixelworks engineers constantly push video performance to keep manufacturers of consumer electronics and professional displays worldwide on the leading edge. The company is headquartered in San Jose, CA.

For more information, please visit the company’s Web site at www.pixelworks.com.

Flamel Technologies (FLML) Announces FDA Approval of Bloxiverz

LYON, FRANCE — (Marketwired) — 06/03/13 — Flamel Technologies (NASDAQ: FLML) today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s New Drug Application (NDA) for Bloxiverz™ (neostigmine methylsulfate), a drug used intravenously in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery. Flamel expects to launch Bloxiverz™ in July 2013 in 0.5 and 1.0 mg/mL strengths.

“We are extremely excited and pleased to receive this FDA approval for Bloxiverz™, the first product from the portfolio of Éclat products acquired in March 2012,” said Mike Anderson, Chief Executive Officer of Flamel.

Bloxiverz™ is the first FDA-approved version of neostigmine, even though other versions of neostigmine have been on the market as unapproved, grandfathered products under the Food, Drug and Cosmetic Act of 1938. Today, neostigmine is the most common agent used for the reversal of the effects of other agents used for neuromuscular blocks.

“Based on our marketing experience, we believe that hospitals will welcome the addition of Bloxiverz™ as an FDA-approved version of neostigmine,” continued Mr. Anderson. “In addition, unapproved versions of neostigmine have been in short supply for nearly a year, which may add to the need for a reliable source of FDA-approved product.”

Safety Information
The most common adverse reactions during treatment include bradycardia, nausea and vomiting. Atropine or glycopyrrolate should be administered prior to Bloxiverz to minimize the risk of bradycardia. Bloxiverz should be used with caution in patients with arrhythmias, recent acute coronary syndrome, vagotonia, hyperthyroidism, myasthenia gravis, epilepsy or peptic ulcer. Because of the possibility of hypersensitivity in an occasional patient, atropine and medications to treat anaphylaxis should always be readily available. Large doses of Bloxiverz administered when neuromuscular blockade is minimal can produce neuromuscular dysfunction. The dose of Bloxiverz should be reduced if recovery from neuromuscular blockade is nearly complete.

About Bloxiverz (neostigmine)
Bloxiverz (neostigmine) is a cholinesterase inhibitor that inhibits the hydrolysis of acetylcholine by competing with acetylcholine for attachment to acetylcholinesterase at sites of cholinergic transmission. It enhances cholinergic action by facilitating the transmission of impulses across neuromuscular junctions. Neostigmine’s ability to increase synaptic acetylcholine levels underlies its effectiveness in reversing neuromuscular blockade produced by neuromuscular blocking agents used during surgery. Neostigmine does not readily cross the blood-brain barrier and therefore does not significantly affect cholinergic function in the central nervous system.

About Flamel Technologies. Flamel Technologies SA’s (NASDAQ: FLML) business model is to blend high-value internally developed products with its leading drug delivery capabilities. The Company has a proprietary pipeline of niche specialty pharmaceutical products, while its drug delivery platforms are focused on the goal of developing safer, more efficacious formulations of drugs to address unmet medical needs. Its partnered pipeline includes biological and chemical drugs formulated with its Medusa® and Micropump® (and its applications to the development of liquid formulations, i.e. LiquiTime™ and of abuse-deterrent formulations Trigger Lock™) proprietary drug delivery platforms. Several Medusa-based products have been successfully tested in clinical trials. The Company has developed products and manufactures Micropump-based microparticles under FDA-audited GMP guidelines. Flamel Technologies has collaborations with a number of leading pharmaceutical and biotechnology companies, including GlaxoSmithKline (Coreg CR®, carvedilol phosphate). The Company is headquartered in Lyon, France and has operations in St. Louis, Missouri, USA, and manufacturing facilities in Pessac, France. Additional information may be found at www.flamel.com.

Safe Harbor
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including certain plans, expectations, goals and projections regarding financial results, product developments and technology platforms. All statements that are not clearly historical in nature are forward-looking, and the words “anticipate,” “assume,” “believe,” “expect,” “estimate,” “plan,” “will,” “may,” and similar expressions are generally intended to identify forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control that could cause actual results to differ materially from those contemplated in such forward-looking statements. These risks include risks that the continued integration of Éclat Pharmaceuticals may not be successful or that certain payment acceleration events may be triggered; the reacquisition of the exclusive rights to develop and commercialize IFN-β XL worldwide and identification of an alternative strategic partner for the program may not be successful; the identified opportunities will not result in shorter-term, high value results; clinical trial results may not be positive or our partners may decide not to move forward; products in the development stage may not achieve scientific objectives or milestones or meet stringent regulatory requirements; products in development may not achieve market acceptance; competitive products and pricing may hinder our commercial opportunities; we may not be successful in identifying and pursuing opportunities to develop our own product portfolio using Flamel’s technology; and the risks associated with our reliance on outside parties and key strategic alliances. These and other risks are described more fully in Flamel’s Annual Report on Form 20-F for the year ended December 31, 2012 that has been filed with the Securities and Exchange Commission (SEC). All forward-looking statements included in this release are based on information available at the time of the release. We undertake no obligation to update or alter our forward-looking statements as a result of new information, future events or otherwise.

IBM and FalconStor (FALC) Team Up to Create Backup Appliance for the Midmarket

FalconStor VTL With Deduplication to be Integrated With IBM Servers and Storage for Midmarket IBM Customers

MELVILLE, N.Y., June 3, 2013 (GLOBE NEWSWIRE) — FalconStor Software, Inc. (Nasdaq:FALC), a market leader in disk-based data protection, today announced that it has entered into a partnership with IBM through IBM’s Indirect OEM (IOEM) program. Under the program, FalconStor^® Virtual Tape Library (VTL) with deduplication software will be integrated with IBM servers and storage to address the needs of IBM midmarket customers.

The new FalconStor VTL IBM Series appliance will be integrated by Avnet Embedded (see related press release, “FalconStor Teams with Avnet Embedded to Create Global Supply Chain“) and will be sold through FalconStor’s channel as well as through IBM business partners who sign up with FalconStor. The new product will be available in North America initially and then throughout the rest of the world early next year.

“In the six years we’ve been partners with FalconStor, our clients have had nothing but praise for the FalconStor VTL backup and deduplication solution. Many of them have been asking for an IBM-based appliance for some time,” said Ken Scott, director of storage sales for Cima Solutions Group. “The FalconStor VTL IBM Series appliance addresses the needs of small to medium-size businesses for which IBM’s ProtecTIER is much more than they need. With this new appliance, we can serve the IBM-based midmarket more effectively – shortening sales cycles and getting customers up and running faster.”

“ServIT has been selling FalconStor VTL software and appliances to meet the data protection needs of the midmarket with great success,” said Craig Jacquez, business development director for ServIT. “The FalconStor VTL solution helps our customers migrate to disk-based backup and recovery, dramatically reduce the backup window and optimize tape for archiving – or eliminate tape altogether. Delivered on the IBM hardware platform, the new system expands our product offering and enhances our ability to give IBM customers exactly what they need.”

“The partnership between FalconStor and IBM is a big win for both companies. IBM midmarket customers now have a comprehensive data protection solution specifically designed for them, and our channel partners gain access to a large new market,” said Gary Quinn, chief operating officer for FalconStor Software. “Enterprise-class data protection and optimization is not just for large enterprises. This joint offering provides the mid-size IBM data center with the same robust, reliable, award-winning technology that is enjoyed by so many of the largest IT operations in the world today.”

About the FalconStor VTL IBM Series appliance

The new FalconStor VTL IBM Series appliance consists of FalconStor VTL software integrated with IBM System x3650 M4 Express servers and IBM System Storage EXP2512 Express Storage enclosures, manufactured and quality-tested by Avnet Technology Solutions. The FalconStor VTL solution provides enterprise-class disk-based backup and deduplication to businesses of all sizes. It optimizes backup speed and performance, minimizes backup windows and makes data secure, available and easy to recover. FalconStor VTL solutions offer several deduplication methods so that customers can tailor to meet the needs of their business.

Pricing and availability

The FalconStor VTL IBM Series appliance and pricing will be available in North America at the end of August and will be rolled out to Europe and Asia-Pacific in Q1 2014.

About FalconStor Software

FalconStor Software, Inc. (Nasdaq:FALC) is a market leader in disk-based data protection. The company’s mission is to transform traditional backup and disaster recovery into next-generation service-oriented data protection. Built upon an award-winning platform, FalconStor solutions deliver disk-based backup, continuous data protection, WAN-optimized replication and disaster recovery automation. FalconStor solutions are available through a worldwide network of partners, including solution providers, top-tier strategic partners and major OEMs. Thousands of customers worldwide, from small businesses to Fortune 100 enterprises, entrust their data to FalconStor solutions. FalconStor maintains headquarters in Melville, N.Y., and offices throughout Europe and the Asia Pacific region. For more information, visit www.falconstor.com or call 1-866-NOW-FALC (866-669-3252).

Follow us on Twitter – Watch us on YouTube – Connect with us on LinkedIn

FalconStor and FalconStor Software are registered trademarks of FalconStor Software, Inc., in the U.S. and other countries. All other company and product names contained herein may be trademarks of their respective holders.

Links to websites or pages controlled by parties other than FalconStor are provided for the reader’s convenience and information only. FalconStor does not incorporate into this release the information found at those links nor does FalconStor represent or warrant that any information found at those links is complete or accurate. Use of information obtained by following these links is at the reader’s own risk.

CONTACT: Roman Kichorowsky
         FalconStor Software, Inc.
         631-773-4303
         roman.kichorowsky@falconstor.com

         Kathryn Ghita
         Metis Communications
         617-236-0500
         falconstor@metiscomm.com

TESARO (TSRO) and the ENGOT Developing Niraparib for Ovarian Cancer

CHICAGO, June 3, 2013 (GLOBE NEWSWIRE) — TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, and the European Network of Gynecological Oncological Trial Groups (ENGOT), a network of national and regional clinical trial organizations, today announced a partnership for the Phase 3 clinical development of niraparib, an orally active, potent poly (ADP-ribose) polymerase (PARP) inhibitor.

The collaboration between TESARO and ENGOT will facilitate and promote the Phase 3 clinical trial of niraparib in patients with ovarian cancer at leading European cancer centers. Major goals of this partnership include optimizing the scientific and clinical impact of the Phase 3 protocol design, accelerating and streamlining selection of investigators and clinical site management, and expediting patient enrollment and publication of data from this trial.

“As an organization dedicated to gynecological cancer research and treatment, we look forward to partnering with TESARO to accelerate the development of niraparib for patients with ovarian cancer,” said Dr. Mansoor Raza Mirza, Medical Director of the Nordic Society of Gynecologic Oncology Clinical Trial Unit. “We are pleased to support clinical research initiatives for this innovative and potentially new class of cancer therapeutics.”

“We are excited to be working with ENGOT to advance the treatment paradigm for patients with ovarian cancer, where significant unmet medical need still exists,” said Dr. Mary Lynne Hedley, President of TESARO. “We look forward to opening this global study to patients in mid-2013 and are pleased to have ENGOT supporting enrollment at key European trial sites.”

This double blind, placebo-controlled, international Phase 3 trial of niraparib is planned to enroll 360 patients with high grade serous, platinum sensitive, relapsed ovarian cancer. Patients will enroll into one of two independent cohorts based on germline BRCA mutation status. Within each cohort, patients will be randomized 2:1 to receive niraparib or placebo, and will be continuously treated with placebo or 300 milligrams of niraparib until progression. The primary endpoint of this study is progression free survival. Secondary endpoints include patient reported outcomes, chemotherapy free interval length, and overall survival.

About The European Network of Gynecological Oncological Trial Groups (ENGOT)

ENGOT is a pan-European Network of Gynecological Oncological Trial Groups supported by and part of the European Society of Gynecological Oncology (ESGO). ESGO is an independent not-for-profit scientific society which was founded as a forum for healthcare professionals dedicated to the care of women with gynecological cancer. The ultimate aim of ESGO is to improve the survival and quality of life of women by contributing to the prevention, treatment and study of gynecological cancer and education professionals worldwide. For more information, please visit www.engot.org and www.esgo.org.

About TESARO

TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients by acquiring, developing and commercializing safer and more effective therapeutics. For more information, visit www.tesarobio.com.

To the extent that statements contained in this press release are not descriptions of historical facts regarding TESARO, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “anticipate,” “estimate,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the initiation of future clinical trials, availability of data from ongoing clinical trials, expectations for regulatory approvals, and other matters that could affect the availability or commercial potential of our drug candidates. TESARO undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see TESARO’s Form 10-K for the year ended December 31, 2012.

CONTACT: Investor/Media Contact:
         Jennifer Davis
         Sr. Director, Corporate Development & Investor Relations
         +1.781.325.1116 or jdavis@tesarobio.com

Clovis Oncology’s (CLVS) Rucaparib Encouraging Results in Solid Tumors

Clovis Oncology (NASDAQ:CLVS) today announced initial findings from an ongoing Phase I/II monotherapy study of rucaparib, the Company’s oral, potent, small molecule poly (ADP-ribose) polymerase (PARP) inhibitor being developed for the treatment of ovarian cancer. Initial results from the Phase I dose-escalation portion of this Phase I/II study are being presented for the first time today at a poster session during the American Society of Clinical Oncology (ASCO) Annual Meeting 2013 in Chicago.

“Oral rucaparib is a potent PARP inhibitor active in patients with ovarian, breast and pancreatic cancers. Clinically meaningful results have been seen in the rucaparib monotherapy Phase I trial; 89% of patients with ovarian cancer demonstrated a clinical benefit. Increasing evidence suggests that genetic analysis of ovarian tumors can help identify patients who derive benefit from PARP inhibitor therapy – best known predictors are mutations in BRCA genes, either at germline or somatic level, but there are likely other predictive mutations as well. The Clovis development program seeks to exploit these new insights and I am pleased to be jointly leading their larger-scale trials to assess the full clinical potential of this well-tolerated drug in ovarian cancer,” said Professor Jonathan Ledermann, Professor of Medical Oncology & Director, Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute.

“These initial results suggest that rucaparib is both well-tolerated and predictably absorbed, and provides meaningful clinical benefit to certain ovarian cancer patients,” said Patrick J. Mahaffy, President and CEO of Clovis Oncology. “Once we identify the recommended Phase II dose, we look forward to commencing the late-stage development program in platinum-sensitive ovarian cancer in 2H13. This comprises two trials – a biomarker study which will refine the definition of patients beyond those with mutant BRCA who may benefit from rucaparib, and a Phase III pivotal trial in all patients with a stratified efficacy analysis in genetically-defined groups, including somatic and germline BRCA mutations as well as a broader population with mutations beyond BRCA, utilizing insights from the biomarker study.”

The Phase I dose escalation portion of the study is open to patients with all solid tumors. Study objectives were typical for a Phase I trial, including determining safety and tolerability, evaluating the pharmacokinetic profile, identifying the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) as well as the preliminary efficacy signals in various solid tumors.

Thirty-seven patients have been treated with rucaparib monotherapy in this study as of May 2013, in once-daily (QD) and twice-daily (BID) dosing cohorts, up to 300 mg QD and 480 mg BID. Dose-escalation continues and the MTD has not yet been reached.

Patients have received a median of four previous anticancer regimens and over half have received three or more previous therapies. Twenty-one patients (57%) have breast tumors, 10 patients (27%) have ovarian/peritoneal tumors and six patients (16%) have other solid tumors.

Key data from the study presented at ASCO include:

Evidence of Activity

Objective responses have been observed in ovarian, breast and pancreatic cancer patients with germline BRCA mutations. Durable disease control has been observed in heavily pre-treated ovarian cancer patients across all dose levels, with a disease control rate of 89% (stable disease or better beyond 12 weeks after study initiation in 8 of 9 ovarian cancer patients). The disease control rate for germline BRCA mutant ovarian cancer patients was 100% (7 of 7). Measurable disease was not a requirement for entry into the dose escalation phase of the study, precluding systematic response analysis.

Safety and Tolerability

Safety data to date shows rucaparib to be well-tolerated, which is important for a drug intended to be used in a maintenance setting. There were 19 patients (54%) with treatment-related adverse events. The most common adverse events attributed to rucaparib therapy include fatigue (23%), nausea (14%) and decreased appetite (11%). No patient experienced a treatment-related adverse event that led to study drug discontinuation and no grade 3/4 myelosuppression has been observed in any patient. There have been two treatment related grade 3 toxicities: one patient with grade 3 nausea and one patient with grade 3 fatigue.

Pharmacokinetics

Oral rucaparib has attractive pharmacokinetic properties as a potential oral cancer therapeutic. Patients receiving BID doses above 240 mg experienced consistently high plasma drug concentrations throughout the 24-hour period, which is likely important for optimal activity. Intra- and inter-patient variability was also low, which is advantageous for uniform flat dosing strategies.

The poster, titled “A Phase I Dose Escalation and Pharmacokinetic Study of Continuous Oral Rucaparib in Patients with Advanced Solid Tumors,” is being presented on Monday, June 3, 8:00am – 11:45am CDT, in S Hall A2, Poster Board: 7E at McCormick Place in Chicago. The poster will also be available at www.clovisoncology.com.

About Rucaparib

Rucaparib is an oral, potent inhibitor of PARP1 and PARP2 in development for the treatment of ovarian cancer. Rucaparib is currently in two Company-sponsored Phase I clinical studies; one to determine the maximum tolerated dose (MTD) of oral rucaparib administered on a daily basis as monotherapy; and a second trial to determine the MTD of oral rucaparib that can be combined with intravenous platinum chemotherapy for the treatment of solid tumors. Once the optimal dose and schedule have been established in the Phase I portion of the monotherapy study, the Company will initiate a Phase II expansion cohort to assess efficacy in selected ovarian cancer patients. The Company expects to initiate a biomarker study in platinum-sensitive ovarian cancer patients in the third quarter of 2013, as well as the pivotal Phase III study in platinum-sensitive ovarian cancer patients in late 2013.

About Clovis Oncology

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops diagnostic tools that direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado, and has additional offices in San Francisco, California and Cambridge, UK.

To the extent that statements contained in this press release are not descriptions of historical facts regarding Clovis Oncology, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the initiation of future clinical trials, availability of data from ongoing clinical trials, expectations for regulatory approvals, and other matters that could affect the availability or commercial potential of our drug candidates. Clovis Oncology undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see Clovis Oncology’s Annual Report on Form 10-K for the year ended December 31, 2012 and its other reports filed with the Securities and Exchange Commission.

Alliance Announces Commitments for Senior Secured Term Loan

Company Increases 2013 Full Year Guidance for Decrease in Net Debt

Alliance HealthCare Services, Inc. (NASDAQ: AIQ), a leading national provider of outpatient diagnostic imaging and radiation therapy services, announced that it has obtained commitments from lenders with respect to a new senior secured credit agreement.

Howard Aihara, executive vice president and chief financial officer stated, “Our ability to refinance our new senior secured term loan on such favorable terms is a clear testament to the improvements in our business performance and the strength of our balance sheet. The financing represents yet another positive step in our ongoing effort to maximize the efficiency of our capital structure, while providing the flexibility and cash flow necessary to execute upon our strategic initiatives, including ongoing reduction of our debt. This new facility will allow us to significantly reduce our interest rate and associated interest expense on an ongoing basis, which will translate into increased cash flow for the current fiscal year and beyond. The Company intends to use the net proceeds from this new term loan agreement to finance the repayment of our existing credit agreement and to redeem a portion of our outstanding senior notes. We are appreciative of the support we received from our lead bank, Credit Suisse, our existing lenders who renewed their commitments and a significant number of new lenders.”

Debt Refinancing Highlights

• Debt refinancing will save the Company $12 million in cash interest expense annually and approximately $7 million in 2013
• Company increases full year guidance for decrease in net debt by $7 million
• Interest rate decreases to LIBOR plus 3.25% with 1.00% LIBOR floor representing cash savings of approximately $9 million annually
• The prior Credit Agreement had interest rate of LIBOR plus 5.25% with 2.00% LIBOR floor
• Significant over-subscription allowed Alliance to upsize term loan from $340 million to $420 million; $80 million upsize to be used to call $80 million of 8.0% Senior Notes, further reducing annual cash interest expense by $3 million

Senior Secured Term Loan Refinancing

Alliance’s new senior secured credit agreement will be comprised of a $420 million term loan maturing June 2019 and a $50 million revolving credit facility maturing June 2018. Interest on the term loan is expected to be calculated, at Alliance’s option, at a base rate plus a 2.25% margin or LIBOR plus a 3.25% margin, subject to a 1.00% LIBOR floor. Prior to the refinancing of its senior secured term loan, Alliance was paying either a base rate plus a 4.25% margin or LIBOR plus a 5.25% margin with a 2.00% LIBOR floor. Excluding the $80 million upsize in the term loan, the change in interest rate on the term loan would save Alliance approximately $9 million in cash interest on an annualized basis.

Interest on the revolving credit facility is expected to be calculated, at Alliance’s option, at a base rate plus an applicable margin of between 2.00% and 2.25% or LIBOR plus an applicable margin of between 3.00% and 3.25%, subject to a 1.00% LIBOR floor. The applicable margins under the revolving credit facility will be based on Alliance’s applicable leverage ratio as calculated under the new senior secured credit agreement. Alliance will pay a 0.50% upfront fee on the amount of the revolving credit facility, and the term loan will be funded at 99.5% of the principal amount. Alliance will also pay a 0.50% per annum fee on the unused amount of the revolving credit facility, subject to a step-down to 0.375% based on Alliance’s applicable leverage ratio. Closing of the new senior secured credit agreement is subject to completion of satisfactory documentation and satisfaction of other closing conditions.

Alliance intends to use the net proceeds from the new senior secured credit agreement to finance the repayment of the $325 million outstanding aggregate principal balance of its existing credit agreement and to call for redemption $80 million in principal amount of its 8% Senior Notes. Alliance expects to use the remaining borrowings under the new senior secured credit agreement to pay fees and expenses related to the new senior secured term loan and to pay the call premium related to the redemption of the 8% Senior Notes. Alliance’s new senior secured credit agreement is expected to close on or about June 3, 2013. The redemption will be effected pursuant to the terms of the indenture governing the 8% Senior Notes, and Alliance intends to initiate the redemption on or around the date of closing of the new senior secured term loan.

Full Year 2013 Guidance Update

As a result of the decrease in interest rates under the new senior secured term loan, Alliance is updating its guidance impacted by the increase in cash flow. On an annualized basis, the Company expects to lower interest expense by approximately $12 million and expects 2013 interest expense to decrease by $7 million, based on the closing date of the facility. The Company’s guidance for decrease in total long-term debt, net of the change in cash and cash equivalents, excluding fees and expenses related to the refinancing, is now expected to range from $32 to $42 million, which is an increase from the prior range of $25 to $35 million. There are no other changes in Alliance’s previously announced 2013 guidance expected to result from the new senior secured credit agreement.

About Alliance HealthCare Services

Alliance HealthCare Services is a leading national provider of advanced outpatient diagnostic imaging and radiation therapy services based upon annual revenue and number of systems deployed. Alliance focuses on MRI, PET/CT and CT through its Imaging division and radiation therapy through its Oncology division. With approximately 1,800 team members committed to providing exceptional patient care and exceeding customer expectations, Alliance provides quality clinical services for over 1,000 hospitals and other healthcare partners in 44 states. Alliance operates 487 diagnostic imaging and radiation therapy systems. The Company is the nation’s largest provider of advanced diagnostic mobile imaging services and one of the leading operators of fixed-site imaging centers, with 129 locations across the country. Alliance also operates 28 radiation therapy centers, including 17 dedicated stereotactic radiosurgery facilities, many of which are operated in conjunction with local community hospital partners, providing treatment and care for cancer patients. With 17 stereotactic radiosurgery facilities in operation, Alliance is among the leading providers of stereotactic radiosurgery nationwide.

Forward-Looking Statements

This press release contains forward-looking statements relating to future events, including statements related to the terms of the new senior secured credit agreement, the closing of the new senior secured credit agreement and the anticipated use of the proceeds therefrom, including the proposed redemption of $80 million in principal amount of the 8% Senior Notes, and the Company’s 2013 guidance, including the impact of the new senior secured term loan on the Company’s guidance for decrease in total debt, net of the change in cash and cash equivalents.

In this context, forward-looking statements often address the Company’s expected future business and financial results and often contain words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks” or “will.” Forward-looking statements by their nature address matters that are uncertain and subject to risks. Such uncertainties and risks include: changes in financial results and guidance in the event of a restatement or review of the Company’s financial statements; the nature, timing and amount of any such restatement or other adjustments; the Company’s ability to make timely filings of its required periodic reports under the Securities Exchange Act of 1934; issues relating to the Company’s ability to maintain effective internal control over financial reporting and disclosure controls and procedures; the Company’s high degree of leverage and its ability to service its debt; factors affecting the Company’s leverage, including interest rates; the risk that the counterparties to the Company’s interest rate swap agreements fail to satisfy their obligations under these agreements; the Company’s ability to obtain financing; the effect of operating and financial restrictions in the Company’s debt instruments; the accuracy of the Company’s estimates regarding its capital requirements; the effect of intense levels of competition in the Company’s industry; changes in the methods of third party reimbursements for diagnostic imaging and radiation oncology services; fluctuations or unpredictability of the Company’s revenues, including as a result of seasonality; changes in the healthcare regulatory environment; the Company’s ability to keep pace with technological developments within its industry; the growth or lack thereof in the market for imaging, radiation oncology and other services; the disruptive effect of hurricanes and other natural disasters; adverse changes in general domestic and worldwide economic conditions and instability and disruption of credit markets; difficulties the Company may face in connection with recent, pending or future acquisitions, including unexpected costs or liabilities resulting from the acquisitions, diversion of management’s attention from the operation of the Company’s business, and risks associated with integration of the acquisitions; and other risks and uncertainties identified in the Risk Factors section of the Company’s Form 10-K for the year ended December 31, 2012, filed with the Securities and Exchange Commission (the “SEC”), as may be modified or supplemented by our subsequent filings with the SEC. These uncertainties may cause actual future results or outcomes to differ materially from those expressed in the Company’s forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company does not undertake to update its forward-looking statements except as required under the federal securities laws.

GigOptix (GIG) Showcasing RF MMICs and E-Band Products at IMS 2013

GigOptix, Inc. (NYSE MKT: GIG), a leading supplier of advanced semiconductor and optical communications components, will showcase several leading RF MMICs and E-Band products.

At IMS booth #2507, GigOptix will showcase the following leading RM MMICs and E-band products:

• iT2008: a high-performance DC to 26.5GHz power amplifier in test fixture
• iT3011E: a high-sensitivity limiting amplifier with operation from DC to 12.5GHz and high-gain
• iT3018E: a leading DC to 12.5GHz, high-gain receiver limiter amplifier with differential output
• iT4036F: a wideband analog phase delay in an evaluation board
• EXP7603: a 71-76GHz low E-band power amplifier
• EXP8602: a 81-86GHz high E-band power amplifier

GigOptix E-Band Products

GigOptix has two low E-band power amplifiers (71-76GHz), the EXP7602 and EXP7603, and two high E-band power amplifiers (81-86GHz), the EXP8602 and EXP8603. GigOptix provides additional E-band solutions including: the EXO8602ZZ Lange Coupler, and the EXE8602 power detector.

GigOptix has also developed highly-integrated silicon-germanium (SiGe) transmitter and receiver chipsets:

• EXU7610: low E-band transmitter
• EXD7610: low E-band receiver
• EXU8610: high E-band transmitter
• EXD8610: high E-band receiver

These SiGe transmitter and receiver chips are expected to be available for sampling at the end of June 2013.

When the EXP7602/3 and EXU7610 are combined, they provide a competitive 2-chip low E-band solution. When the EXP8602/3 is combined with the EXU8610 a compelling 2-chip solution for the high E-band is achieved.

For more information, please visit GigOptix booth #2507 at IMS 2013 or contact your local sales manager via sales@gigoptix.com.

About GigOptix, Inc.

GigOptix is a leading fabless supplier of semiconductor and optical components that enable high speed information streaming that address emerging high growth opportunities in the communications, industrial, defense and avionics industries. The Company offers a broad portfolio of high performance MMIC solutions that enable next generation wireless microwave systems up to 90GHz and drivers, TIAs and TFPS^TM optical modulators for 40 Gbps and 100 Gbps fiber-optic telecommunications and data-communications networks. GigOptix also offers a wide range of digital and mixed-signal ASIC solutions and enables product lifetime extension through its GigOptix Sunset Rescue Program.

Fuwei (FFHL) Films Receives Positive Outcome in Anti-Dumping Review

BEIJING, May 31, 2013 /PRNewswire/ — Fuwei Films (Holdings) Co., Ltd. (Nasdaq: FFHL) (“Fuwei Films” or the “Company”), a manufacturer and distributor of high-quality BOPET plastic films in China, today announced that the United States Court of International Trade, as a result of an administrative challenge brought by Fuwei Films, has found that Fuwei Films’ shipments did not give rise to any anti-dumping duties for the period from November 6, 2008 to October 31, 2009.

On March 18, 2011, Fuwei Films filed an administrative lawsuit against the US Department of Commerce (“the Department”) regarding the anti-dumping duty of 30.91% imposed as a result of the first round of anti-dumping administrative review. The Department, after recalculating the rate following administrative challenge, found that Fuwei Films’ shipments resulted in a level of dumping that was “de minimis” which carries no associated anti-dumping duties. All of Fuwei Films’ importers will receive a full refund of all of the monies deposited as anti-dumping duties for entries made during this period, plus interest.

Mr. Xiaoan He, Chairman and CEO of Fuwei Films, said, “This is exciting news for the growth of Fuwei Films. We have long maintained that we conduct our business relations according to the highest standards and this ruling supports our claim. We plan to continue to expand overseas markets as well as accelerate the R & D of the optical thick films to be produced on the third production line to remain competitive and increase the revenue of the Company.”

About Fuwei Films

Fuwei Films conducts its business through its wholly owned subsidiary, Fuwei Films (Shandong) Co., Ltd. (“Fuwei Shandong”). Fuwei Shandong develops, manufactures and distributes high-quality plastic films using the biaxial oriented stretch technique, otherwise known as BOPET film (biaxially oriented polyethylene terephthalate). Fuwei’s BOPET film is widely used to package food, medicine, cosmetics, tobacco, and alcohol, as well as in the imaging, electronics, and magnetic products industries.

Safe Harbor

This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are subject to risks. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company’s reports filed with the U.S. Securities and Exchange Commission which, among other things, include both the short and long-term effects of the global financial crisis on the Company and the BOPET film industry; competition in the BOPET film industry; growth of, and risks inherent in, the BOPET film industry in China; uncertainty as to future profitability and our ability to obtain adequate financing for our planned capital expenditure requirements; uncertainty as to our ability to continuously develop new BOPET film products and keep up with changes in BOPET film technology; risks associated with possible defects and errors in our products; uncertainty as to our ability to protect and enforce our intellectual property rights; uncertainty as to our ability to attract and retain qualified executives and personnel; and uncertainty in acquiring raw materials on time and on acceptable terms, particularly in view of the volatility in the prices of petroleum products in recent years. The forward-looking information provided herein represents the Company’s estimates as of the date of the press release, and subsequent events and developments may cause the Company’s estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company’s estimates of its future financial performance as of any date subsequent to the date of this press release. Actual results of our operations may differ materially from information contained in the forward-looking statements as a result of the risk factors.

For more information, please contact:

In China:

Miss Lysander Lee
Investor Relations Officer
Phone: +86-133-615-59266
Email: fuweiIR@fuweifilms.com

In the U.S.:

Ms. Leslie Wolf-Creutzfeldt
Investor Relations
Grayling
Phone: +1-646-284-9472
Email: leslie.wolf-creutzfeldt@grayling.com

LipoScience (LPDX) Presents Data At The National Lipid Association Annual Scientific Sessions

Four clinical studies highlight the importance of measuring lipoprotein particles to manage cardiovascular disease

RALEIGH, N.C., May 31, 2013 /PRNewswire/ — LipoScience, Inc. (NASDAQ: LPDX), a diagnostic company pioneering a new field of personalized nuclear magnetic resonance (NMR) diagnostics to advance the quality of patient care, today announced the presentation of data from four clinical studies at the National Lipid Association (NLA) Annual Scientific Sessions in Las Vegas, Nevada. The data demonstrate the value of measuring lipoprotein particles in a patient’s blood sample as a tool for cardiovascular disease (CVD) management.

“Consistently, research is linking low-density lipoprotein particle number (LDL-P) and high-density lipoprotein particle number (HDL-P) to cardiovascular disease progression and events. The studies presented at NLA validate the importance of looking at lipoprotein particle numbers to individualize patient management and minimize cardiovascular risk,” said Robert Honigberg, MD, Chief Medical Officer of LipoScience.

The data are to be presented today in the following posters during sessions starting at 12:30 p.m. PDT:

• Heterogeneity of LDL and HDL Particle Concentration in Subjects Meeting LDL-Cholesterol Goals
  Presenters:  James Underberg, MD and Gregory Pokrywka, MD
  Abstract/Poster #: 101

• HDL Particle Number (HDL-P) Distribution in Patients with Angiographic Coronary Artery Disease on Lipid-Lowering Medication
  Lead presenter: Hector Malave, MD
  Abstract/Poster #: 102

• Lipoprotein Particle Number (LDL-P) Distribution in Polycystic Ovary Syndrome Patients
  Lead presenter: Jason Reingold, MD
  Abstract/Poster #: 105

• Discordance Between LDL Particle Number (LDL-P) and LDL-Cholesterol (LDL-C) Among Patients Treated at Two Medical Systems
  Presenters: Kari Uusinarkaus, MD and Thomas White, MD
  Abstract/Poster #: 107

In each of the studies, LDL-P and HDL-P were measured using LipoScience’s proprietary NMR spectroscopy technology. The studies found that 55 to 75 percent of patients display discordance between low-density lipoprotein cholesterol (LDL-C) and LDL-P levels. Measuring lipoprotein particle number provides an opportunity to personalize patient management.

In one study, “Heterogeneity of LDL and HDL Particle Concentration in Subjects Meeting LDL-Cholesterol Goals,” investigators studied the variations of LDL-P and HDL-P numbers to determine residual CVD risk in more than 6,500 patients who were at target LDL-C and high- density lipoprotein cholesterol (HDL-C) levels. The study found considerable discordance between cholesterol levels and particle numbers for both LDL and HDL, suggesting that quantifying lipoprotein particle concentrations may better identify residual risk for cardiovascular events than measuring cholesterol levels alone.

For more information on LipoScience and the studies being presented at NLA, please visit www.liposcience.com or the LipoScience booth at exhibit hall space #314.

About LipoScience, Inc.
LipoScience, Inc. is pioneering a new field of personalized diagnostics based on nuclear magnetic resonance (NMR) technology. The company’s first proprietary diagnostic test, the NMR LipoProfile^® test, measures the number of low-density lipoprotein particles (LDL-P) in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. To date, over 9 million NMR LipoProfile tests have been ordered.  LipoScience’s automated clinical analyzer, Vantera^®, has been cleared by the U.S. Food and Drug Administration (FDA).  It requires no previous knowledge of NMR technology to operate and has been designed to dramatically simplify complex technology through ease of use and walk-away automation. The Vantera Clinical Analyzer will be placed with national and regional clinical laboratories.

LipoScience is driving toward becoming a clinical standard of care by decentralizing its technology and expanding its menu of personalized diagnostic tests to address a broad range of cardiovascular, metabolic and other diseases. For further information on LipoScience, please visit www.liposcience.com and www.theparticletest.com.